Science and Practice　産科婦人科臨床シリーズ　6　女性ヘルスケア

出版社： 中山書店
著者：
発行日： 2019-10-18
分野： 臨床医学：外科  >  産婦人科学
ISBN： 9784521747668
電子書籍版： 2019-10-18 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

商品紹介

思春期・妊娠期・生殖期・更年期・老年期を対象とする産科婦人科領域で，女性ヘルスケアは4つ目のサブスペシャリティとして重要性が増している．
月経回数の増加による生殖期の弊害と閉経後40～50年に及ぶ老年期はこれまでの常識を覆し，生殖内分泌学・婦人科腫瘍学に加え，運動器・泌尿器・皮膚・循環器など幅広い分野の研究成果が欠かせなくなっている．
全身を診る知識と的確な診断技術を紹介．

目次

  • 1章　女性ヘルスケア概論

    2章　女性ヘルスケアの初期診断
    　問診・診察・検査
    　症候学
    　　無月経・不正出血・帯下
    　　下腹部痛・下腹部腫瘤・腰痛
    　　抑うつ・動悸・めまい・頭痛
    　　乳房腫瘤・乳汁分泌

    3章　女性ヘルスケアに特異的な疾患と対応
    　性分化疾患
    　子宮筋腫
    　子宮内膜症
    　子宮腺筋症
    　更年期障害/HRT（ホルモン補充療法）
    　漢方療法
    　フレイル・サルコペニア
    　骨盤臓器脱
    　骨粗鬆症

    4章　女性ヘルスケアに関連する課題と対応
    　脂質・糖代謝の変化
    　心疾患
    　皮膚疾患
    　子宮頸がん検診とHPVワクチン
    　性暴力・虐待への対応
    　性の健康教育

    5章　乳腺疾患
    　乳癌
    　乳腺症・線維腫・嚢胞

    6章　女性ヘルスケアと遺伝性疾患
    　HBOC・Lynch症候群
    　カウンセリング

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 女性ヘルスケア概論

P.12 掲載の参考文献
1) 水沼英樹. 更年期医療から女性医学へ-その歩みと今後の展望. 日本女性医学学会雑誌 2018 ; 25 : 175-8.
 
2) 厚生科学審議会地域保健健康増進栄養部会. 「健康日本21 (第二次)」中間報告 (概要). https://www.mhlw.go.jp/content/000378312.pdf
 
3) Kurabayashi T, et al. Pregnancy-induced hypertension is associated with maternal history and a risk of cardiovascular disease in later life : Japanese cross-sectional study. Maturitas 2013 ; 75 : 227-31.
 
4) Nagai K, et al. Disease history and risk of comorbidity in women's life course : a comprehensive analysis of the Japan Nurses' Health Study baseline survey. BMJ Open 2015 ; 5 : e006360.
PubMed
5) 厚生労働省平成29年簡易生命表の概要. https://www.mhlw.go.jp/toukei_hakusho/
 
6) 厚生労働省. 平成26年度版国民労働白書 健康長寿社会の実現に向けて～健康・予防元年～. https://www.mhlw.go.jp/wp/hakusyo/kousei/14/
 
7) 日野林俊彦. 平均初経年齢の時代推移と現状-7回の全国初潮調査の結果をもとに. 産婦人科の実際 1992 ; 41 : 939-44.
 
8) 田中敏章ほか. 縦断的検討による女児の思春期の成熟と初経年齢の標準化. 日児誌 2005 ; 109 : 1232-42.
 
9) 日本産科婦人科学会生殖・内分泌委員会報告. わが国思春期少女の体格,月経周期, 体重変動, 希望体重との相互関係について-アンケートによる. 日産婦誌 1997 ; 49 : 367-77.
 
10) Yasui T, et al. Factors associated with premature ovarian failure, early menopause and earlier onset of menopause in Japanese women. Maturitas 2012 ; 72 : 249-55.
PubMed
11) Yasui T, et al. Association of endometriosis-related infertility with age at menopause. Maturitas 2011 ; 69 : 279-83.
PubMed
12) 内閣府平成27年度少子化社会対策白書. http://www8.cao.go.jp/shoushi/shoushika/whitepaper/measures/w-2015/27webhonpen/index.html
 
13) 内閣府男女共同参画局平成23年度版男女共同参画白書. http://www.gender.go.jp/about_danjo/whitepaper/h23/zentai/html/zuhyo/zuhyo01-02-01.html
 
14) Brown MC, et al. Cardiovascular disease risk in women with pre-eclampsia : systematic review and meta-analysis. Eur J Epidemiol 2013 ; 28 : 1-19.
PubMed
15) Bellamy L, et al. Type 2 diabetes mellitus after gestational diabetes : a systematic review and meta-analysis. Lancet 2009 ; 373 : 1773-9.
PubMed
16) Kugishima Y, et al. Risk factors associated with the development of postpartum diabetes in Japanese women with gestational diabetes. BMC Pregnancy Childbirth 2018 ; 18 : 19. doi : 10.1186/s12884-017-1654-4.
 
17) Iino K, et al. Blood pressure during pregnancy is a useful predictive maker for hypertension and dyslipidemia later in life, a population-based, cross-sectional study. Maturitas 2016 ; 87 : 84-8.
PubMed
18) Mu F, et al. Endometriosis and Risk of Coronary Heart Disease. Circ Cardiovasc Qual Outcomes 2016 ; 9 : 257-64.
PubMed
19) Uimari O, et al. Uterine fibroids and cardiovascular risk. Hum Reprod 2016 ; 31 : 2689-703.
PubMed
20) Gilbert EW, et al. Comorbidities and complications of polycystic ovary syndrome : an overview of systematic reviews. Clin Endocrinol (Oxf) 2018 ; 89 : 683-99.
PubMed
21) Harder T, et al. Birth weight and subsequent risk of type 2 diabetes : a meta-analysis. Am J Epidemiol 2007 ; 165 : 849-57.
PubMed
22) Katanoda K, et al. Impact of birth weight on adult-onset diabetes mellitus in relation to current body mass index : The Japan Nurses' Health Study. J Epidemiol 2017 ; 27 : 428-434.
PubMed
23) Castelo-Branco C. Management of Turner syndrome in adult life and beyond. Maturitas 2014 ; 79 : 471-5.
PubMed
24) Joy E, et al. 2016 Update on eating disorders in athletes : a comprehensive narrative review with a focus on clinical assessment and management. Br J Sports Med 2016 ; 50 : 154-62.
PubMed

2章 女性ヘルスケアの初期診断

P.19 掲載の参考文献
日本産科婦人科学会/日本産婦人科医会編・監. 産婦人科診療ガイドライン 婦人科外来編 2017. 東京 : 日本産科婦人科学会 ; 2017.
 
日本産科婦人科学会編・監. 産婦人科研修の必修知識 2016-2018. 東京 : 日本産科婦人科学会 ; 2016.
 
日本女性医学学会編. 女性医学ガイドブック 更年期医療編 2014年度版. 東京 : 金原出版 ; 2014.
 
日本女性医学学会編. 女性医学ガイドブック 思春期・性成熟期編 2016年度版. 東京 : 金原出版 ; 2016.
 
P.28 掲載の参考文献
1) American Academy of Pediatrics. Menstruation in girls and adolescents : using the menstrual cycle as a vital sign. Pediatrics 2006 ; 118 : 2245-50.
 
2) 日本産科婦人科学会生殖・内分泌委員会報告〔思春期少女の肥満と性機能に関する小委員会 (平成7年度-平成8年度) 検討結果報告〕わが国思春期少女の体格, 月経周期, 体重変動, 希望体重との相互関係について : アンケートによる. 日産婦誌 1997 ; 49 : 367-77.
 
3) 久具宏司. 月経異常, 排卵障害. 金澤一郎, 永井良三総編集. 今日の診断指針. 第7版. 東京 : 医学書院 ; 2015. p.460-3.
 
4) The Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril 2008 ; 90 : S219-25.
PubMed
P.32 掲載の参考文献
1) Bickerton N, Visvanathan D. Abdominal pain. In : Hollingworth T, editor. Differential Diagnosis in Obstetrics and Gynaecology : An A-Z. 2nd edition. CRC Press ; 2016.
 
2) 日本緩和医療学会. がん疼痛の薬物療法に関するガイドライン 2010年版. 東京 : 金原出版 ; 2010.
 
3) Fernandes HM. Pelvic Pain. In : Hollingworth T, editor. Differential Diagnosis in Obstetrics and Gynaecology : An A-Z. 2nd edition. CRC Press ; 2016.
 
P.38 掲載の参考文献
1) 日本性感染症学会. 淋菌感染症. 性感染症 診断・治療ガイドライン 2016. 日性感染症会誌 2016 ; 27 Suppl : 53-60.
 
2) Wald A. Herpes simplex virus type 2 transmission : risk factors and virus shedding. Herpes 2004 ; 11 : 130A-7A.
PubMed
3) 日本性感染症学会. 性器ヘルペス. 性感染症 診断・治療ガイドライン 2016. 日性感染症会誌 2016 ; 27 Suppl : 67-72.
 
4) Maw RD, et al. An international survey of patients with genital warts : perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998 ; 9 : 571-8.
PubMed
5) Takamatsu K, Kitawaki J. Annual report of the Women's Health Care Committee, Japan Society of Obstetrics and Gynecology, 2017. J Obstet Gynaecol Res 2018 ; 44 : 13-26.
 
P.45 掲載の参考文献
1) 菊地俊暁. 抑うつ状態. 金沢一郎, 永井良三編. 今日の診断指針. 第7版. 東京 : 医学書院 ; 2015. p.150-2.
 
2) 高橋三郎, 大野裕監訳. DSM-5 精神疾患の診断・統計マニュアル. 東京 : 医学書院 ; 2014. p.160-1.
 
3) 水野篤. 動悸. 今日の臨床サポート. 2017/1/26.
 
4) 北川泰久ほか. めまい. 症状からアプローチするプライマリケア. 日本医師会雑誌 2011 ; 140 特別号 (2) : S189-94.
 
5) 肥塚泉. めまい診療のすすめ方. 日耳鼻会報 2013 ; 116 : 1282-9.
 
6) 国際頭痛学会・頭痛分類委員会. 国際頭痛分類 第2版 (ICHD-II). 日本頭痛学会誌 2004 ; 31 : 13-188.
 
7) 慢性頭痛の診療ガイドライン作成委員会, 日本神経学会, 日本頭痛学会. 慢性頭痛の診療ガイドライン 2013. 東京 : 医学書院 ; 2013.
 
8) Kurth T, et al. Migraine and risk of cardiovascular disease in women. JAMA 2006 ; 296 : 283-91.
PubMed
P.48 掲載の参考文献
1) 青野敏博, 苛原稔編. 産婦人科ベッドサイドマニュアル. 第7版. 東京 : 医学書院 ; 2018.
 

3章 女性ヘルスケアに特異的な疾患と対応

P.59 掲載の参考文献
1) She ZY, Yang WX. Molecular mechanisms involved in mammalian primary sex determination. J Mol Endocrinol 2014 ; 53 : R21-37.
PubMed
2) 小西郁生. 女性性器の発生学. 藤井信吾編. 新女性医学大系 1. 性器の発生・形態・機能. 東京 : 中山書店 ; 2001. p.3-21.
 
3) Kelsey TW, et al. Data-driven assessment of the human ovarian reserve. Mol Hum Reprod 2012 ; 18 : 79-87.
PubMed
4) Hughes IA, et al. Consensus statement on management of intersex disorders. Arch Dis Child 2006 ; 91 : 554-63.
PubMed
5) 緒方勤ほか. 性分化異常症の管理に関する合同見解. 日児誌 2008 ; 112 : 565-78.
 
6) 堀川玲子. 性分化疾患初期対応. 日児誌 2011 ; 115 : 7-12.
 
7) The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, mullerian anomalies and intrauterine adhesions. Fertil Steril 1988 ; 49 : 944-55.
PubMed
8) Grimbizis GF, et al. The ESHRE/ESGE consensus on the classification of female genital tract congenital anomalies. Hum Reprod 2013 ; 28 : 2032-44.
PubMed
9) 石川玲奈ほか. 思春期に月経困難症を来した片側腎無形成を伴う重複子宮, 重複腟, 片側腟閉鎖-OHVIRA症候群-の1例. 神奈川産婦人科学会誌 2016 ; 53 : 2-5.
 
10) 平池修. 子宮・腟奇形に対する形成術. 小児外科 2014 ; 46 : 490-6.
Medical*Online
11) Dahm-Kahler P, et al. Human uterus transplantation in focus. Br Med Bull 2016 ; 117 : 69-78.
PubMed
12) Dohnert U, et al. Gonadectomy in complete androgen insensitivity syndrome : Why and when? Sex Dev 2017 ; 11 : 171-4.
PubMed
P.75 掲載の参考文献
1) Verkauskiene R, et al. Puberty in children born small for gestational age. Horm Res Paediatr 2013 ; 80 : 69-77.
PubMed
2) 広井正彦. 生殖・内分泌委員会報告〔思春期少女の肥満と性機能に関する小委員会 (平成7年度-平成8年度) 検討結果報告〕わが国思春期少女の体格, 月経周期, 体重変動, 希望体重との相互関係について : アンケートによる. 日産婦誌 1997 ; 49 : 367-77.
 
3) Thomas F, et al. International variability of ages at menarche and menopause : patterns and main determinants. Hum Biol 2001 ; 73 : 271-90.
PubMed
4) 日本産科婦人科学会生殖・内分泌委員会報告. 日産婦誌 2017 ; 69 : 1429-40.
 
5) Practice Committee of American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril 2008 ; 90 (5 Suppl) : S219-25.
 
6) Kodama M, et al. Efficacy of hormone therapy for osteoporosis in adolescent girls after hematopoietic stem cell transplantation : a longitudinal study. Fertil Steril 2011 ; 95 : 731-5.
PubMed
7) 甲村弘子. 小児がん治療と卵巣機能障害. 小児外科 2008 ; 40 : 681-5.
Medical*Online
8) Tanaka T, et al. Frequencies of spontaneous breast development and spontaneous menarche in Turner syndrome in Japan. Clin Pediatr Endocrinol 2015 ; 24 : 167-73.
PubMed
9) 日本産科婦人科学会生殖・内分泌委員会報告. 日産婦誌 2007 ; 59 : 868-86.
 
10) 岩佐武ほか. ストレス・摂食調節因子によるゴナドトロピン分泌調節. 臨床婦人科産科 2010 ; 64 : 1293-9.
 
11) Hotta M, et al. The response of plasma adrenocorticotropin and cortisol to corticotropine-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. J Clin Endocrinol Metab 1986 ; 62 : 319-24.
 
12) Maimoun L, et al. Endocrine disorders in adolescent and young female athletes. Impact on growth, menstrual cycles, and bone mass acquisition. J Clin Endocrinol Metab 2014 ; 99 : 4037-50.
 
13) Nattiv A, et al. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc 2007 ; 39 : 1867-82.
PubMed
14) Sundgot-Borgen J, Torstveit MK. Prevalence of eating disorders in elite athletes is higher than in the general population. Clin J Sport Med 2004 ; 14 : 25-32.
PubMed
15) De Souza MJ, et al. 2014 Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad : 1st International Conference held in San Francisco, California, May 2012 and 2nd International Conference held in Indianapolis, Indiana, May 2013. Br J Sports Med 2014 ; 48 : 289.
 
16) 日本産科婦人科学会/日本女性医学学会編・監. 女性アスリートのヘルスケアに関する管理指針. Q8 続発性無月経の管理法は? 東京 : 日本産科婦人科学会 ; 2017. p.16-7.
 
17) Strokosch GR, et al. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa : a double-blind, placebo-controlled study. J Adolesc Health 2006 ; 39 : 819-27.
 
18) 高橋一広, 倉知博久. 女性の肥満・肥満症. 日本医師会雑誌 2014 ; 143 : 44-8.
 
19) Coulam CB, et al. Incidence of premature ovarian failure. Obstet Gynecol 1986 ; 67 : 604-6.
PubMed
20) 日本産科婦人科学会/日本産婦人科医会編・監. 産婦人科診療ガイドライン 婦人科外来編 . 東京 : 日本産科婦人科学会 ; 2017. p.140-2.
 
21) Bertelloni S, et al. Hormonal management of complete androgen insensitivity syndrome from adolescence onward. Horm Res Paediatr 2011 ; 76 : 428-33.
PubMed
22) ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005 ; 11 : 513-25.
PubMed
23) 日本産科婦人科学会/日本産婦人科医会編・監. 産婦人科診療ガイドライン 婦人科外来編 . 東京 : 日本産科婦人科学会 ; 2017. p.234-40.
 
24) Committee on Gynecologic Practice. ACOG Committee Opinion Number 540 : risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills. Obstet Gynecol 2012 ; 120 : 1239-42.
PubMed
25) Zhu H, et al. Oral contraceptive use and risk of breast cancer : a meta-analysis of prospective cohort studies. Eur J Contracept Reprod Health Care 2012 ; 17 : 402-14.
PubMed
26) Gierisch JM, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers : a systematic review. Cancer Epidemiol Biomarkers Prev 2013 ; 22 : 1931-43.
PubMed
27) 日本産科婦人科学会編・監. OC・LEPガイドライン 2015年版. 東京 : 日本産科婦人科学会 ; 2015. p.57-9.
 
28) International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives : collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007 ; 370 : 1609-21.
PubMed
29) 日本産科婦人科学会編・監. OC・LEPガイドライン 2015年版. 東京 : 日本産科婦人科学会 ; 2015. p.60-1.
 
30) Gallo MF, et al. Combination contraceptives : effects on weight. Cochrane Database Syst Rev 2014 Jan 29 ; (1) : CD003987.
 
31) 日本産科婦人科学会編・監. OC・LEPガイドライン 2015年版. 東京 : 日本産科婦人科学会 ; 2015. p.105.
 
32) Safety of oral contraceptives for teenagers. ACOG Committee opinion : Committee on Adolescent Health Care number 90--February 1991. Int J Gynaecol Obstet 1992 ; 37 : 309-12.
PubMed
33) Scholes D, et al. Oral contraceptive use and bone density change in adolescent and young adult women : a prospective study of age, hormone dose, and discontinuation. J Clin Endocrinol Metab 2011 ; 96 : 1380-7.
 
P.89 掲載の参考文献
1) Stewart EA, et al. Epidemiology of uterine fibroids : a systematic review. BJOG 2017 ; 124 : 1501-12.
PubMed
2) 厚生労働省. 平成26年患者調査 (傷病分類編) -傷病別年次推移表. https://www.mhlw.go.jp/toukei/saikin/hw/kanja/10syoubyo/dl/h26syobyo.pdf
 
3) McWilliams MM, Chennathukuzhi VM. Recent advances in uterine fibroid etiology. Semin Reprod Med 2017 ; 35 : 181-9.
PubMed
4) Tsuyoshi H, Yoshida Y. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. Cancer Sci 2018 ; 109 : 1743-52.
PubMed
5) Maekawa R, et al. Genome-wide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas. PLoS One 2013 ; 8 : e66632.
PubMed
6) Munro MG, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011 ; 113 : 3-13.
PubMed
7) Dubreuil J, et al. Diffusion-weighted MRI and 18F-FDG-PET/CT imaging : competition or synergy as diagnostic methods to manage sarcoma of the uterus? : a systematic review of the literature. Nucl Med Commun 2017 ; 38 : 84-90.
PubMed
8) Tsuyoshi H, Yoshida Y. Diagnostic imaging using positron emission tomography for gynecological malignancy. J Obstet Gynaecol Res 2017 ; 43 : 1687-99.
PubMed
9) Aarts JW, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev 2015 ; (8) : CD003677.
PubMed
10) Bosteels J, et al. Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities. Cochrane Database Syst Rev 2015 ; (2) : CD009461.
 
11) Practice Committee of the American Society for Reproductive Medicine. Electronic address : ASRM@asrm.org ; Practice Committee of the American Society for Reproductive Medicine. Removal of myomas in asymptomatic patients to improve fertility and/or reduce miscarriage rate : a guideline. Fertil Steril 2017 ; 108 : 416-25.
PubMed
12) Vitagliano A, et al. Uterine fibroid size modifications during pregnancy and puerperium : evidence from the first systematic review of literature. Arch Gynecol Obstet 2018 ; 297 : 823-35.
PubMed
13) Milazzo GN, et al. Myoma and myomectomy : poor evidence concern in pregnancy. J Obstet Gynaecol Res 2017 ; 43 : 1789-804.
PubMed
14) Dedes I, et al. Outcome and risk factors of cesarean delivery with and without cesarean myomectomy in women with uterine myomatas. Arch Gynecol Obstet 2017 ; 295 : 27-32.
PubMed
15) Bryant-Smith AC, et al. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2018 ; (4) : CD000249.
PubMed
16) Liu JP, et al. Herbal preparations for uterine fibroids. Cochrane Database Syst Rev 2013 ; (4) : CD005292.
PubMed
17) Lethaby A, et al. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev 2017 ; (11) : CD000547.
PubMed
18) Moroni RM, et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev 2015 ; (3) : CD010854.
PubMed
19) Lagana AS, et al. Endometrial preparation with Dienogest before hysteroscopic surgery : a systematic review. Arch Gynecol Obstet 2017 ; 295 : 661-7.
PubMed
20) Sangkomkamhang US, et al. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database Syst Rev 2013 ; (2) : CD008994.
 
21) Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med 2015 ; 372 : 1646-55.
PubMed
22) Keung JJ, et al. Uterine artery embolization : a review of current concepts. Best Pract Res Clin Obstet Gynaecol 2018 ; 46 : 66-73.
PubMed
23) Donnez J, et al. The current place of medical therapy in uterine fibroid management. Best Pract Res Clin Obstet Gynaecol 2018 ; 46 : 57-65.
PubMed
24) Murji A, et al. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev 2017 ; (4) : CD010770.
PubMed
P.98 掲載の参考文献
1) Vercellini P, et al. Adenomyosis : a deja vu? Obstet Gynecol Surv 1993 ; 48 : 789-94.
PubMed
2) Vercellini P, et al. Uterine adenomyosis and in vitro fertilization outcome : a systematic review and meta-analysis. Hum Reprod 2014 ; 29 : 964-77.
PubMed
3) Garcia-Solares J, et al. Pathogenesis of uterine adenomyosis : invagination or metaplasia? Fertil Steril 2018 ; 109 : 371-9.
PubMed
4) Templeman C, et al. Adenomyosis and endometriosis in the California teachers study. Fertil Steril 2008 ; 90 : 415-24.
PubMed
5) 日本産科婦人科学会編・監. 子宮腺筋症. 産婦人科研修の必修知識 2016-2018. 東京 : 日本産科婦人科学会 ; 2016. p.540-5.
 
6) McCluggage WG, et al. Tamoxifen-associated postmenopausal adenomyosis exhibits stromal fibrosis, glandular dilatation and epithelial metaplasias. Histopathology 2000 ; 37 : 340-6.
PubMed
7) Varras M, et al. Effects of tamoxifen on the human female genital tract : review of the literature. Eur J Gynaecol Oncol 2003 ; 24 : 258-68.
PubMed
8) Tremellen K, et al. Adenomyosis is a potential cause of recurrent implantation failure during IVF treatment. Aust Nz J Obstet Gynaecol 2011 ; 51 : 280-3.
 
9) Sallam HN, et al. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Sys Rev 2006 (1) : CD004635.
 
10) Osuga Y, et al. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis : a randomized. double-blind, multicenter, placebo-controlled study. Fertil Steril 2017 ; 108 : 673-8.
PubMed
11) Osuga Y, et al. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res 2017 ; 43 : 1441-8.
PubMed
12) Cho S, et al. Clinical effects of levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol 2008 ; 198 : 373. e1-7.
 
13) Osada H, et al. Surgical procedure to conserve the uterus for future pregnancy in patients suffering from massive adenomyosis. Reprod Biomed Online 2011 ; 22 : 94-9.
PubMed
14) Fujishita A, et al. Modified reduction surgery for adenomyosis : a preliminary report of the transverse H incision technique. Gynecol Obstet Invest 2004 ; 57 : 132-8.
PubMed
15) 錢鴻武ほか. 子宮内膜症によるダグラス窩完全閉塞症例に対するTLH-逆行性子宮全摘術の導入. 日エンドメトリオーシス会誌 2011 ; 32 : 165-8.
 
16) Tamura H, et al. Complications and outcomes of pregnant women with adenomyosis in Japan. Reprod Med Biol 2017 ; 16 : 330-6.
PubMed
P.113 掲載の参考文献
1) Tanase Y, et al. Factors that differentiate between endometriosis-associated ovarian cancer and benign ovarian endometriosis with mural nodules. Magn Reson Med Sci 2018 ; 17 : 231-7.
PubMed
2) 日本産科婦人科学会/日本産婦人科医会編・監. 産婦人科診療ガイドライン-婦人科外来編 2017. 東京 : 日本産科婦人科学会 ; 2017.
 
3) Hart RJ, et al. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane Database Syst Rev 2008 ; (2) : CD004992.
PubMed
4) Sutton CJ, et al. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 1994 ; 62 : 696-700.
PubMed
5) Abbott J, et al. Laparoscopic excision of endometriosis : a randomized, placebo-controlled trial. Fertil Steril 2004 ; 82 : 878-84.
PubMed
6) Harada T, et al. Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis. Am J Obstet Gynecol 1997 ; 176 : 593-7.
PubMed
7) Nagai K, et al. Disease history and risk of comorbidity in women's life course : a comprehensive analysis of the Japan Nurses' Health Study baseline survey. BMJ Open 2015 ; 5 : e006360.
PubMed
8) Mu F, et al. Endometriosis and risk of coronary heart disease. Circ Cardiovasc Qual Outcomes 2016 ; 9 : 257-64.
PubMed
9) Kanyama A, et al. Endothelial function and oxidative stress in women with endometriosis. J Aichi Med Univ Assoc 2009 ; 38 ; 1-8.
 
10) Kinugasa S, et al. Increased asymmetric dimethyl arginine and enhanced inflammation are associated with impaired vascular reactivity in women with endometriosis. Atherosclerosis 2011 ; 219 : 784-8.
 
11) Santoro L, et al. Endothelial dysfunction but not increased carotid intima-media thickness in young European women with endometriosis. Hum Reprod 2012 ; 27 : 1320-6.
 
12) Tani A, et al. Arterial stiffness is increased in young women with endometriosis. J Obstet Gynaecol 2015 ; 35 : 711-5.
PubMed
13) Melo AS, et al. Unfavorable lipid profile in women with endometriosis. Fertil Steril 2010 ; 93 : 2433-6.
PubMed
14) Reese KA, et al. Endometriosis in an adolescent population : the Emory experience. J Pediatr Adolesc Gynecol 1996 ; 9 : 125-8.
 
15) Laufer MR, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997 ; 10 : 199-202.
 
16) Glavind MT, et al. Endometriosis and pregnancy complications : a Danish cohort study. Fertil Steril 2017 ; 107 : 160-6.
PubMed
17) Vercellini P, et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence : a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2013 ; 92 : 8-16.
PubMed
18) Harada R, et al. Effects of gonadotropin-releasing hormone agonist on vascular reactivity, oxidative stress, and plasma levels of asymmetric dimethylarginine, inflammatory markers, glucose, and lipids in women with endometriosis. J Aichi Med Univ Assoc 2014 ; 42 : 1-10.
 
19) Yim SF, et al. Prospective randomized study of the effect of "add-back" hormone replacement on vascular function during treatment with gonadotropin-releasing hormone agonists. Circulation 1998 ; 98 : 1631-5.
PubMed
P.126 掲載の参考文献
1) 日本産科婦人科学会生殖・内分泌委員会報告. 日産婦誌 2007 ; 59 : 868-86.
 
2) Gunning MN, et al. Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life? Climacteric 2017 ; 20 : 222-7.
PubMed
3) Elting MW, et al. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000 ; 15 : 24-8.
PubMed
4) Carmina E, et al. A 20-year follow-up of young women with polycystic ovary syndrome. Obstet Gynecol 2012 ; 119 : 263-9.
PubMed
5) Alsamarai S, et al. Criteria of polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009 ; 94 : 4961-70.
 
6) Kim HJ, et al. Polycystic ovary morphology : age-based ultrasound criteria. Fertil Steril 2017 ; 108 : 548-53.
PubMed
7) Schmidt J, et al. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOD) : a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab 2011 ; 96 ; 2178-85.
 
8) Winters SJ, et al. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000 ; 73 : 724-9.
PubMed
9) Pinola P, et al. Androgen profile through life in women with polycystic ovary syndrome : a nordic multicenter collaboration study. J Clin Endocrinol Metab 2015 ; 100 : 3400-7.
PubMed
10) Huddleston HG, et al. Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia : results of a longitudinal study with community controls. Clin Endocrinol 2017 ; 87 : 775-82.
PubMed
11) Kudesia R, et al. Menopausal implications of polycystic ovarian syndrome. Semin Reprod Med 2014 ; 32 : 222-9.
PubMed
12) Yin O, et al. Association between polycystic ovary syndrome and hot flash presenting during the midlife period. Menopause 2018 ; 25 : 691-6.
PubMed
13) de Groot PC, et al. PCOS, coronary heart disease, stroke and the influence of obesity : a systematic review and meta-analysis. Hum Reprod Update 2011 ; 17 : 495-500.
PubMed
14) Moran LJ, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome : a systemic review and meta-analysis. Hum Reprod Update 2010 ; 16 : 347-63.
 
15) Echiburu B, et al. Metabolic profile in women with polycystic ovary syndrome across adult life. Metabolism 2016 ; 65 : 776-82.
PubMed
16) Pinola P, et al. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit and adverse metabolic profile through life. Fertil Steril 2017 ; 107 : 788-95.
PubMed
17) Livadas S, et al. Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome : evidence from 1345 women with the syndrome. Eur J Endocrinol 2014 ; 171 : 301-9.
PubMed
18) Talbott EO, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000 ; 20 : 2414-21.
PubMed
19) Cibura D, et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000 ; 15 : 785-9.
 
20) Elting MW, et al. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001 ; 16 : 556-60.
 
21) Kakoly NS, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS : a systemic review and meta-regression. Hum Reprod Update 2018 ; 24 : 455-67.
 
22) Jaliseh HK, et al. Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women : a long-term population-based follow-up study. Fertil Steril 2017 ; 108 : 1078-84.
 
23) Kurabayashi T, et al. Ovarian infertility is associated with cardiovascular disease risk factors in later life : a Japanese cross-sectional study. Maturitas 2016 ; 83 : 33-9.
PubMed
24) Schmidt J, et al. Cardiovascular disease and risk factors in PCOS women of postmenopausal age : a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011 ; 96 ; 3794-803.
PubMed
25) Shaw LJ, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival : results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemic Syndrome Evaluation. J Clin Endocrinol Metab 2008 ; 93 : 1276-84.
PubMed
26) Krentz AJ, et al. Searching for polycystic ovary syndrome in postmenopausal women : evidence for a dose-effects association with prevalent cardiovascular disease. Menopause 2007 ; 14 : 284-92.
PubMed
27) Pierpoint T, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998 ; 51 : 581-6.
PubMed
28) Wild S, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up : a retrospective cohort study. Clin Endocrinol 2000 ; 52 : 595-600.
 
29) Meun C, et al. High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease : The Rotterdam Study. J Clin Endocrinol Metab 2018 ; 103 : 1622-30.
PubMed
30) Merz CNB, et al. Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Women's Health 2016 ; 25 : 875-81.
PubMed
31) Lenart-Lipinska M, et al. Polycystic ovary syndrome : clinical implication in perimenopause. Prz Menopauzalny 2014 ; 13 : 348-51.
PubMed
32) Khatibi A, et al. Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women : The Women's Health in the Lund Area (WHILA) Study. Climacteric 2007 ; 10 : 386-92.
PubMed
33) Polotsky AJ, et al. Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. J Clin Endocrinol Metab 2014 ; 99 : 2120-7.
PubMed
34) Welt CK, Carmina E. Lifecycle of polycystic ovary syndrome (PCOS) : from in utero to menopause. J Clin Endocrinol Metab 2013 ; 98 : 4629-38.
PubMed
35) Haoula Z, et al. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012 ; 27 : 1327-31.
PubMed
36) Barry JA, et al. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome : a systematic review and meta-analysis. Hum Reprod Update 2014 ; 20 : 748-58.
PubMed
37) Chittenden BG, et al. Polycystic ovary syndrome and the risk of gynaecological cancer : a systematic review. Reprod Biomed Online 2009 ; 19 : 398-405.
 
38) Shreeve N, et al. Poor sleep in PCOS ; is melatonin the culprit? Hum Reprod 2013 ; 28 : 1348-53.
PubMed
39) Fernandez RC, et al. Sleep disturbances in women with polycystic ovary syndrome : prevalence, pathophysiology, impact and management strategies. Nat Sci Sleep 2018 ; 10 : 45-64.
PubMed
40) Veltman-Verhulst SM, et al. Emotional distress is a common risk in women with polycystic ovary syndrome : a systematic review and meta-analysis of 28 studies. Hum Reprod 2012 ; 18 : 638-51.
PubMed
41) Bromberger JT, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition. Arch Gen Psychiatry 2010 ; 67 : 598-607.
PubMed
42) Jedel E, et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod 2010 ; 25 : 450-6.
PubMed
43) Chaudhari AP, et al. Anxiety, depression, and quality of life in women with polycystic ovary syndrome. Indian J Psychol Med 2018 ; 40 : 239-46.
 
44) Gilbert EW, et al. Comorbidities and complications of polycystic ovary syndrome : an overview of systematic reviews. Clin Endocrinol (Oxf) 2018 ; 89 : 683-99. doi : 10.1111/cen.13828. [Epub ahead of print]
 
45) Duleba AJ, et al. Is PCOS an inflammatory process? Fertil Steril 2012 ; 97 : 7-12.
PubMed
46) Schmidt J, et al. High androgen levels protect against hypothyroidism. Acta Obstet Gynecol Scand 2017 ; 96 : 39-46.
PubMed
P.148 掲載の参考文献
1) Cope E. Physical changes associated with the post-menopausal years. In : Cambell S, editor. The Management of the Menopause & Post-Menopausal Years. Baltimore : University Park Press ; 1976.
 
2) Speroff L, Fritz MA. Menopause and the perimenopausal transition. In : Fritz MA, Speroff L, editors. Clinical Gynecologic Endocrinology and Infertility. 8th ed. Philadelphia : Lippincott Williams & Wilkins ; 2011. p.673-748.
 
3) 日本産科婦人科学会教育・用語委員会報告 : 「本邦女性の閉経年齢について」に関する委員会提案理由. 日産婦誌 1995 ; 47 : 449-51.
 
4) Utian WH. Menopause : a modern perspective from a controversial history. Maturitas 1997 ; 26 : 73-82.
PubMed
5) Wilbush J. La Menespausie : The birth of a syndrome. Maturitas 1979 ; 1 : 145-51.
PubMed
6) 山本祥子. 更年期の構築-医療が描く女性像. http://bleedingornot.blogspot.com/2005/10/blog-post_02.html (最終閲覧日2018年11月19日)
 
7) 原葉子. 日本近代における「更年期女性」像の形成-「内分泌」をめぐる言説の考察を中心に. ジェンダー研究 2014 ; 17 : 103-18. http://www2.igs.ocha.ac.jp/wp-content/uploads/2016/02/17-Hara.pdf (最終閲覧日2018年11月19日)
 
8) 日本産科婦人科学会編. 産科婦人科用語集・用語解説集. 改訂第4版. 東京 : 金原出版 ; 2018.
 
9) CAMS : the Council of Affiliated Menopause Societies. CAMS menopause-related definitions. 日更医誌 2000 ; 8 : 116-9.
 
10) Harlow SD, et al. STRAW+10 Collaborative Group : Executive summary of the Stages of Reproductive Aging Workshop+10 : addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012 ; 97 : 1159-68.
 
11) Takamatsu K, et al. Study of psychosocial factors in Japanese patients suffering from menopausal disorders. J Obstet Gynaecol Res 2004 ; 30 : 309-15.
PubMed
12) 相良洋子. 更年期障害の治療における心身医学的視点の重要性. 心身医学 2018 ; 58 : 688-95.
Medical*Online
13) 高松潔. 更年期不定愁訴のみかた. 日産婦誌 2004 ; 56 : N651-9.
 
14) National Institutes of Health. National Institute of Health State-of-the-Science Conference Statement : management of menopause-related symptoms. Ann Intern Med 2005 ; 142 (12 Pt 1) : 1003-13.
 
15) 高松潔. 更年期障害に対する治療法の選択. 麻生武志編. 更年期医療のコツと落とし穴. 東京 : 中山書店 ; 2005. p.82-3.
 
16) 日本産科婦人科学会/日本女性医学学会編・監. ホルモン補充療法ガイドライン 2017年度版. 東京 : 日本産科婦人科学会 ; 2017.
 
17) 若槻明彦. 更年期障害. 日産婦誌 2009 ; 61 : N238-42.
 
18) Vilar-Gonzalez S, et al. Mechanism of hot flashes. Clin Transl Oncol 2011 ; 13 : 143-7.
PubMed
19) Hauser GA. The climacteric syndrome. In : Lauritzen C, Studd J, editors. Current Management of the Menopause. Taylor & Francis ; 2005. p.57-78.
 
20) Whiteman MK, et al. Risk factors for hot flashes in midlife women. J Womens Health (Larchmt) 2003 ; 12 : 459-72.
PubMed
21) Freedman RR. Hot flashes : behavioral treatments, mechanisms, and relation to sleep. Am J Med 2005 ; 118 (Suppl 12B) : 124-30.
 
22) Berendsen HH. The role of serotonin in hot flashes. Maturitas 2000 ; 36 : 155-64.
PubMed
23) Wise DD, et al. Tailoring treatment of depression for women across the reproductive lifecycle : the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. CNS Spectr 2008 ; 13 : 647-62.
PubMed
24) Shams T, et al. SSRIs for hot flashes : a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014 ; 29 : 204-13.
PubMed
25) Rance NE, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons : a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013 ; 34 : 211-27.
PubMed
26) Szeliga A, et al. The role of kisspeptin/neurokinin B/dynorphin neurons in pathomechanism of vasomotor symptoms in postmenopausal women : from physiology to potential therapeutic applications. Gynecol Endocrinol 2018 ; 34 : 913-9.
PubMed
27) Mittelman-Smith MA, et al. Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. Proc Natl Acad Sci USA 2012 ; 109 : 19846-51.
PubMed
28) Jayasena CN, et al. Neurokinin B administration induces hot flushes in women. Sci Rep 2015 ; 5 : 8466. doi : 10.1038/srep08466.
 
29) Crandall CJ, et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women's Health Initiative Study. Menopause 2017 ; 24 : 252-61.
PubMed
30) Prague JK, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes : a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2017 ; 389 : 1809-20.
PubMed
31) Sturdee DW, et al. The menopausal hot flush : a review. Climacteric 2017 ; 20 : 296-305.
PubMed
32) Aso T, et al. A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women. J Womens Health 2012 ; 21 : 92-100.
 
33) Miller VM, et al. What's in a name : are menopausal "hot flashes" a symptom of menopause or a manifestation of neurovascular dysregulation? Menopause 2018 ; 25 : 700-3.
PubMed
34) Osterlund MK, Hurd YL. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog Neurobiol 2001 ; 64 : 251-67.
PubMed
35) Georgakis MK, et al. Association of age at menopause and duration of reproductive period with depression after menopause : a systematic review and meta-analysis. JAMA Psychiatry 2016 ; 73 : 139-49.
PubMed
36) Henderson VW, et al. Congnition, mood, and physiological concentrations of sex hormones in the early and late postmenopause. Proc Natl Acad Sci USA 2013 ; 110 : 20290-5.
 
37) Freeman EW, et al. Longitudinal pattern of depressive symptoms around natural menopause. JAMA Psychiatry 2014 ; 71 : 36-43.
PubMed
38) Ryan J, et al. A prospective study of the association between endogenous hormones and depressive symptoms in postmenopausal women. Menopause 2009 ; 16 : 509-17.
 
39) Bromberger JT, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition. Arch Gen Psychiatry 2010 ; 67 : 598-607.
PubMed
40) Kaufert PA, et al. The Manitoba Project : a re-examination of the link between menopause and depression. Maturitas 1992 ; 14 : 143-55.
 
41) 相良洋子. 更年期女性のメンタルケア. 日本女性心身医学会編, 玉田太朗, 本庄英雄編集責任. TEXT BOOK 女性心身医学. 東京 : 永井書店 ; 2006. p.289-95.
 
42) Schmidt PJ. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med 2005 ; 118 (Suppl 12B) : 54-8S.
 
43) Soares CN, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women : a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001 ; 58 : 529-34.
PubMed
44) Steinberg EM, et al. A cross sectional evaluation of perimenopausal depression. J Clin Psychiatry 2008 ; 69 : 973-80.
PubMed
45) Freeman EW, et al. Premenstrual syndrome as a predictor of menopausal symptoms. Obstet Gynecol 2004 ; 103 (5 Pt 1) : 960-6.
 
46) Ayers B, et al. The impact of attitudes towards the menopause on women's symptom experience : a systematic review. Maturitas 2010 ; 65 : 28-36.
PubMed
47) Perquier F, et al. Lifetime endogenous reproductive factors and severe depressive symptoms in postmenopausal women : finding from the E3N cohort. Menopause 2013 ; 20 : 1154-63.
PubMed
48) Maltais ML, et al. Changes in muscle mass and strength after menopause. J Musculoskelet Neuronal Interact 2009 ; 9 : 186-97.
PubMed
49) Phillips SK, et al. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 1993 ; 84 : 95-8.
PubMed
50) Naessen T, et al. Early postmenopausal hormone therapy improves postural balance. Menopause 2007 ; 14 : 14-9.
PubMed
51) Dawson-Basoa ME, Gintzler AR. Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms. Pain 1996 ; 64 : 169-77.
PubMed
52) Rocca WA, et al. Accelerated accumulation of multimorbidity after bilateral oophorectomy : a population-based cohort study. Mayo Clin Proc 2016 ; 91 : 1577-89.
PubMed
53) Blumel JE, et al. Menopause could be involved in the pathogenesis of muscle and joint aches in mid-aged women. Maturitas 2013 ; 75 : 94-100.
PubMed
54) Chlebowski RT, et al. Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause 2013 ; 20 : 600-8.
PubMed
55) Hussain SM, et al. Female hormonal factors and osteoarthritis of the knee, hip and hand : a narrative review. Climacteric 2018 ; 21 : 132-9.
 
56) Yokota M, et al. Symptoms and effects of physical factors in Japanese middle-aged women. Menopause 2016 ; 23 : 974-83.
PubMed
57) Takamatsu K, et al. Evaluation of depressive conditions among Japanese patients at a menopause clinic. J Obstet Gynaecol Res 2004 ; 30 : 42-7.
 
58) Takamatsu K, et al. Mental health of patients visiting an outpatient menopause clinic. Int J Fertil 2003 ; 48 : 252-9.
 
59) Ikeda T, et al. Status of climacteric symptoms among middle-aged to elderly Japanese women : comparison of general healthy women with women presenting at a menopause clinic. J Obstet Gynaecol Res 2005 ; 31 : 164-71.
 
60) Kasuga M, et al. Relation between climacteric symptoms and ovarian hypofunction in middle-aged and older Japanese women. Menopause 2004 ; 11 (6 Pt 1) : 631-8.
 
61) Ward T, et al. Women's mid-life health experiences in urban UK : an international comparison. Climacteric 2010 ; 13 : 278-88.
PubMed
62) Thurston RC, et al. Adiposity and reporting of vasomotor symptoms among midlife women : the study of women's health across the nation. Am J Epidemiol 2008 ; 167 : 78-85.
 
63) Baber RJ. East is east and West is west : perspectives on the menopause in Asia and The West. Climacteric 2014 ; 17 : 23-8.
 
64) Boulet MJ, et al. Climacteric and menopause in seven South-east Asian countries. Maturitas 1994 ; 19 : 157-76.
 
65) Islam MR, et al. Prevalence of menopausal symptoms in Asian midlife women : a systematic review. Climacteric 2015 ; 18 : 157-76.
PubMed
66) Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world : a systematic review. Climacteric 2007 ; 10 : 197-204.
PubMed
67) Hunter MS, et al. The International Menopause Study of Climate, Altitude, Temperature (IMS-CAT) and vasomotor symptoms. Climacteric 2013 ; 16 : 8-16.
 
68) 池田俊之, 牧田和也. 更年期女性の血管運動神経症状の季節変動に関する検討. 日更医誌 2010 ; 18 : 229-32.
 
69) Williams RE, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008 ; 11 : 32-43.
PubMed
70) The North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms : 2015 position statement of The North American Menopause Society. Menopause 2015 ; 22 : 1155-74.
PubMed
71) 高松潔, 小川真里子. エクオールと更年期障害. Modern Physician 2018 ; 38 : 393-6.
 
72) Soleymani M, et al. Dietary patterns and their association with menopausal symptoms : a cross-sectional study. Menopause 2019 ; 26 : 365-72.
PubMed
73) Huang AJ, et al. Program to reduce incontinence by diet and exercise investigators : an intensive behavioral weight loss intervention and hot flushes in women. Arch Intern Med 2010 ; 170 : 1161-7.
PubMed
74) Kroenke CH, et al. Effects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative. Menopause 2012 ; 19 : 980-8.
 
75) Chedraui P, et al. Severe menopausal symptoms in middle-aged women are associated to female and male factors. Arch Gynecol Obstet 2009 ; 281 : 879-85.
PubMed
76) 松尾博哉. 精神神経症状主体更年期障害患者に対するparoxetineの有用性に関する検討. 新薬と臨床 2003 ; 52 : 44-51.
 
77) Gallicchio L, et al. Cigarette smoking, estrogen levels, and hot flashes in midlife women. Maturitas 2006 ; 53 : 133-43.
PubMed
78) 千場直美. 更年期女性のストレスが更年期症状に及ぼす影響についての検討. 更年期と加齢のヘルスケア 2007 ; 6 : 61-7.
 
79) Gibson CJ, et al. Associations of intimate partner violence, sexual assault, and posttraumatic stress disorder with menopause symptoms among midlife and older women. JAMA Intern Med 2019 ; 179 : 80-7.
PubMed
80) Schilling C, et al. Current alcohol use is associated with a reduced risk of hot flashes in midlife women. Alcohol Alcohol 2005 ; 40 : 563-8.
PubMed
81) Kim MJ, et al. Association between physical activity and menopausal symptoms in perimenopausal women. BMC Womens Health. 2014 ; 14 : 122. doi : 10.1186/1472-6874-14-122.
 
82) Bailey TG, et al. Exercise training reduces the frequency of menopausal hot flushes by improving thermoregulatory control. Menopause 2016 ; 23 : 708-18.
PubMed
83) Tepper PG, et al. Trajectory Clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the study of Women's Health across the Nation (SWAN). J Clin Endocrinol Metab 2012 ; 97 : 2872-80.
 
84) 高松潔, 小川真里子. 更年期障害. 別冊日本臨牀 内分泌症候群 (第3版) III-その他の内分泌疾患を含めて. 2019 ; p.243-51.
 
85) Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965 ; 12 : 63-70.
 
86) Spielberger CD, et al. Manual for the State-Trait Anxiety Inventory. Palo Alto : Consulting Psychologists Press ; 1970.
 
87) 高松潔, 太田博明. 女性メンタルヘルスケアへのHADS (Hospital Anxiety and Depression Scale) の応用. 産婦人科の世界 2002 ; 54 : 107-13.
 
88) 北村俊則. Hospital Anxiety and Depression Scale (HADS尺度). 精神科診断学 1993 ; 4 : 371-2.
 
89) Sheehan DV, Lecrubier Y. 大坪天平ほか訳. M. I. N. I. 精神疾患簡易構造化面接法日本語版 5.0.0 (2003). 東京 : 星和書店 ; 2003.
 
90) Stahl SM. Antidepressants. In : Stahl's Essential Psychopharmacology : Neuroscientific Basis and Practical Applications. 3rd ed. New York : Cambridge University Press ; 2008. p.511-666.
 
91) Kupperman HS, et al. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953 ; 13 : 688-703.
PubMed
92) 小山嵩夫. 不定愁訴と更年期指数. 産婦治療 2003 ; 87 : 266-70.
Medical*Online
93) 高松潔. 更年期障害. 大内尉義, 秋山弘子編集代表. 新老年学. 第3版. 東京 : 東京大学出版会 ; 2010. p.1231-42.
 
94) 日本産科婦人科学会生殖・内分泌委員会. 日本人女性の更年期症状評価表. 日産婦誌 2001 ; 53 : 883-8.
 
95) iHope International : 健康関連QOL SF-36(R). https://www.sf-36.jp/ (最終閲覧日2018年12月17日)
 
96) 田崎美弥子, 中根允文. WHO QOL26. 東京 : 金子書房 ; 2007.
 
97) 日本ペインクリニック学会. 痛みの基礎知識. https://www.jspc.gr.jp/igakusei/igakusei_hyouka.html (最終閲覧日2018年12月17日)
 
98) 高松潔. 更年期障害治療を極める-基礎知識から最近の話題まで. 東海産科婦人科学会雑誌 2019 ; 55 : 17-30.
 
99) 高松潔ほか. 更年期障害. 臨床婦人科産科 2018 ; 72 : 320-9.
 
100) Webster AD, et al. Quality of life among postmenopausal women enrolled in the Minnesota Green Tea Trial. Maturitas 2017 ; 108 : 1-6.
PubMed
101) 高松潔, 小川真里子. 更年期の諸問題-更年期障害とその対応. 予防医学 2016 ; 58 : 91-100.
Medical*Online
102) Politi MC, et al. Revisiting the duration of vasomotor symptoms of menopause : a meta-analysis. J Gen Intern Med 2008 ; 23 : 1507-13.
PubMed
103) Gartoulla P, et al. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause 2015 ; 22 : 694-701.
PubMed
104) Avis NE, et al. Study of Women's Health Across the Nation : duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015 ; 175 : 531-9.
PubMed
P.160 掲載の参考文献
1) Shoupe D, et al. Elective oophorectomy for benign gynecological disorders. Menopause 2007 ; 14 : 580-5.
PubMed
2) 日本産科婦人科学会/日本女性医学学会編・監. 3. HRTの実際. ホルモン補充療法ガイドライン 2017年度版. 東京 : 日本産科婦人科学会 ; 2017. p.69-93.
 
3) 日本産科婦人科学会/日本女性医学学会編・監. 2. HRTに予想される有害事象. ホルモン補充療法ガイドライン 2017年度版. 東京 : 日本産科婦人科学会 ; 2017. p.40-68.
 
4) de Villiers TJ, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016 ; 19 : 313-5.
 
5) North American Menopause Society. Estrogen and progestogen use in post menopausal women : 2010 statement of The North American Menopause Society. Menopause 2010 ; 17 : 242-55.
 
6) Pinkerton JV, et al. Breast effects of bazedoxifene-conjugated estrogens : a randomized controlled trial. Obstet Gynecol 2013 ; 121 : 959-68.
PubMed
7) Howard BV, et al. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004 ; 110 : 201-6.
PubMed
8) Tribble DL, et al. Variation in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992 ; 93 : 189-99.
PubMed
9) Wakatsuki A, et al. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001 ; 104 : 1773-8.
PubMed
10) Gambacciani M, et al. Dydrogesterone does not reverse the effects of estradiol on endothelium-dependent vasodilation in postmenopausal women : a randomized clinical trial. Maturitas 2002 ; 43 : 117-23.
 
11) Boardman HM, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015 ; 3 : CD002229.
PubMed
12) Hulley S, et al. Randomized trial of estrogen plus progesterone for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998 ; 280 : 605-13.
 
13) Mohammed K, et al. Oral vs transdermal estrogen therapy and vascular events : a systematic review and meta-analysis. J Clin Endocrinol Metab 2015 ; 100 : 4012-20.
PubMed
14) Bath PM, et al. Association between hormone replacement therapy and subsequent stroke : a meta-analysis. BMJ 2005 ; 330 : 342.
PubMed
15) Grodstein F, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann intern Med 2000 ; 133 : 933-41.
PubMed
16) Gu H, et al. Risk of stroke in healthy postmenopausal women during and after hormone therapy : a meta-analysis. Menopause 2014 ; 21 : 1204-10.
PubMed
17) Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women : systematic review and meta-analysis. BMJ 2008 ; 336 : 1227-31.
PubMed
18) Scarabin PY, et al. Estrogen and thromboembolism risk study group : differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003 ; 362 : 428-32.
 
19) Santen RJ, et al. Postmenopausal hormone therapy : an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010 ; 95 : s1-66.
PubMed
20) Pichar JH, et al. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009 ; 92 : 1018-24.
 
21) Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk : individual participant meta-analysis of 52 epidemiological studies. Lancet 2015 ; 385 : 1835-42.
 
22) 日本産科婦人科学会/日本女性医学学会編・監. CQ208 子宮内膜癌治療後のHRTは推奨されるか? ホルモン補充療法ガイドライン 2017年度版. 東京 : 日本産科婦人科学会 ; 2017. p.124-5.
 
23) 日本産科婦人科学会/日本女性医学学会編・監. CQ205 糖尿病を有数する女性にHRTは可能か? ホルモン補充療法ガイドライン 2017年度版. 東京 : 日本産科婦人科学会 ; 2017. p.117-8.
 
P.165 掲載の参考文献
1) 日本産科婦人科学会/日本女性医学学会編・監 ホルモン補充療法ガイドライン 2017年度版. 東京 : 日本産科婦人科学会 ; 2017.
 
2) Matthews KA, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009 ; 54 : 2366-73.
PubMed
3) Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations : analysis of studies published from 1974-2000. Fertil Steril 2001 ; 75 : 898-915.
PubMed
4) Colditz GA, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987 ; 316 : 1105-10.
PubMed
5) Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovas Dis 1995 ; 38 : 199-210.
 
6) Hulley S, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998 ; 280 : 605-13.
PubMed
7) Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002 ; 288 : 321-33.
PubMed
8) Anderson G, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women's Health Initiative randomized controlled trial. JAMA 2004 ; 291 : 1701-12.
PubMed
9) Manson JE, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003 ; 349 : 523-34.
PubMed
10) Salpeter S, et al. Brief report : coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 2006 ; 21 : 363-6.
PubMed
11) Manson JE, et al. Postmenopausal hormone therapy : new questions and the case for new clinical trials. Menopause 2006 ; 13 : 139-47.
PubMed
12) Hodis HN, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016 ; 374 : 1221-31.
PubMed
13) Tuomikoski P, et al. Coronary heart disease mortality and hormone therapy before and after the Women's Health Initiative. Obstet Gynecol 2014 ; 124 : 947-53.
PubMed
14) Mikkola TS, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015 ; 22 : 976-83.
PubMed
P.176 掲載の参考文献
1) Imanishi J, et al. Japanese doctors' attitudes to complementary medicine. Lancet 1999 ; 354 : 1735-6.
PubMed
2) Takeda T, et al. Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines. Int J Clin Oncol 2012 ; 17 : 143-9.
PubMed
3) 武田卓. 女性診療で使えるヌーベル漢方処方ノート. 大阪 : メディカ出版 ; 2017.
 
4) Kitamura M, et al. Relationship between premenstrual symptoms and dysmenorrhea in Japanese high school students. Arch Womens Ment Health 2012 ; 15 : 131-3.
PubMed
5) Knuttinen MG, et al. Blood pool contrast-enhanced magnetic resonance angiography with correlation to digital subtraction angiography : a pictorial review. J Clin Imaging Sci 2014 ; 4 : 63.
PubMed
6) 日本産科婦人科学会/日本産婦人科医会編・監. 産婦人科診療ガイドライン 婦人科外来編 2017. 東京 : 日本産科婦人科学会 ; 2017.
 
7) Takayama S, et al. The traditional kampo medicine tokishakuyakusan increases ocular blood flow in healthy subjects. Evid Based Complement Alternat Med 2014 ; 2014 : 586857.
PubMed
8) Tomita T, et al. Effect of keishibukuryogan, a Japanese traditional kampo prescription, on improvement of microcirculation and oketsu and induction of endothelial nitric oxide : a live imaging study. Evid Based Complement Alternat Med 2017 ; 2017 : 3620130.
PubMed
9) Plotnikoff GA, et al. The TU-025 keishibukuryogan clinical trial for hot flash management in postmenopausal women : results and lessons for future research. Menopause 2011 ; 18 : 886-92.
 
10) Egashira N, et al. Kamishoyosan reduces conditioned fear-induced freezing behavior in socially isolated ovariectomized rats. J Pharmacol Sci 2016 ; 131 : 279-83.
PubMed
11) Park DM, et al. The comparative clinical study of efficacy of Gamisoyo-San (Jiaweixiaoyaosan) on generalized anxiety disorder according to differently manufactured preparations : multicenter, randomized, double blind, placebo controlled trial. J Ethnopharmacol 2014 ; 158 Pt A : 11-7.
 
12) 水沼英樹. 厚生労働科学研究費補助金・循環器疾患・糖尿病等生活習慣対策総合研究事業・平成22年度～平成24年度総合研究報告書. 2013.
 
13) Chen H, et al. Combined treatment with a traditional Chinese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) and alendronate improves bone microstructure in ovariectomized rats. J Ethnopharmacol 2012 ; 142 : 80-5.
PubMed
14) Takeda T, et al. Proliferative effect of Hachimijiogan, a Japanese herbal medicine, in C2C12 skeletal muscle cells. Clin Interv Aging 2015 ; 10 : 445-51.
PubMed
15) Kishida Y, et al. Go-sha-jinki-Gan (GJG), a traditional Japanese herbal medicine, protects against sarcopenia in senescence-accelerated mice. Phytomedicine 2015 ; 22 : 16-22.
PubMed
16) Matsuda Y, et al. Yokukansan in the treatment of behavioral and psychological symptoms of dementia : a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 2013 ; 28 : 80-6.
PubMed
17) Tamiya H, et al. Hypnotics and the occurrence of bone fractures in hospitalized dementia patients : a matched case-control study using a national inpatient database. PLoS One 2015 ; 10 : e0129366.
 
18) Takeda H, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 2008 ; 134 : 2004-13.
PubMed
19) Fujitsuka N, et al. Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin 1. Mol Psychiatry 2016 ; 21 : 1613-23.
PubMed
P.185 掲載の参考文献
1) 中塚幹也. 封じ込められた子ども, その心を聴く-性同一性障害の生徒に向き合う. 岡山 : ふくろう出版 ; 2017.
 
2) オランダ社会文化計画局. インターセックスの状態/性分化疾患と共に生きる : インターセックスの状態/性分化疾患を持つ人々の社会的状況についての探索的調査, 2014年8月. https://docs.wixstatic.com/ugd/0c8e2d_36b9cbb9aa864fca821ad8bf5ab35b25.pdf (2018年12月)
 
3) 中塚幹也. 特集「医療者のためのLGBT, SOGIの基礎知識」. LGBT, SOGIの中での「性同一性障害」とは. Modern Physician 2019 ; 5 : 430-3.
 
4) 中塚幹也. 性同一性障害の現状と治療-性同一性障害診療を取り巻く課題と今後の展望. 医学のあゆみ 2016 ; 256 : 312-6.
 
5) Hembree WC, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons : An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017 ; 102 : 3869-903.
PubMed
6) World Professional Association for Transgender Health (WPATH) : standards of care (SOC) for the health of transsexual, transgender, and gender nonconforming people. ver. 7 (日本語版は『トランスセクシュアル, トランスジェンダー, ジェンダーに非同調な人々のためのケア基準』). https://www.wpath.org/publications/soc (2018年12月)
 
7) 中塚幹也. 性同一性障害に対するホルモン療法. 形成外科 2014 ; 57 : 849-55.
Medical*Online
8) 中塚幹也. 性同一性障害への性別適合手術の保険適用の意義と今後の課題. 月刊保団連 2018 ; 1276 : 39-43.
 
9) 藤田志保ほか. 小学生の頃の性同一性障害当事者のカミングアウト. GID (性同一性障害) 学会雑誌 2015 ; 8 : 33-9.
 
10) 中塚幹也ほか. 性同一性障害の説明と治療を希望する年齢に関する調査. 母性衛生 2006 ; 46 : 543-9.
 
11) 日本精神神経学会・性同一性障害に関する委員会. 性同一性障害に関する診断と治療のガイドライン (第4版). 精神神経学雑誌 2012 ; 114 : 1250-66. 性同一性障害に関する診断と治療のガイドライン (第4版改) 2018年1月20日. https://www.jspn.or.jp/uploads/uploads/files/activity/gid_guideline_no4_20180120.pdf
 
12) 中塚幹也. 若年期の性同一性障害当事者への対応-GnRHアゴニストの使用や手術・ホルモン療法適応年齢の引き下げをめぐって. 精神神経学雑誌 2012 ; 114 : 647-53.
 
13) Gooren LJ. Care of transsexual persons. N Engl J Med 2011 ; 364 : 1251-7.
PubMed
14) 文部科学省. 性同一性障害に係る児童生徒に対するきめ細かな対応の実施等について, 2015年4月30日. http://www.mext.go.jp/b_menu/houdou/27/04/1357468 (2018年12月)
 
15) 文部科学省. 性同一性障害や性的指向・性自認に係る, 児童生徒に対するきめ細かな対応等の実施について (教職員向け). 2015年4月30日. http://www.mext.go.jp/b_menu/houdou/28/04/_icsFiles/afieldfile/2016/04/01/1369211_01.pdf (2018年12月)
 
16) 中塚幹也. 生殖倫理の現況と展望-性の多様性に対する生殖医療の役割. 医学のあゆみ 2017 ; 263 : 349-51.
 
17) 中塚幹也. 性同一性障害当事者と家族形成. 母性衛生 2018 ; 58 : 学3-8.
 
18) Ethics Committee of the American Society for Reproductive Medicine. Access to fertility services by transgender persons : an Ethics Committee opinion. Fertil Steril 2015 ; 104 : 1111-5.
PubMed
19) De Wert G, et al. ESHRE Task Force on Ethics and Law 23 : medically assisted reproduction in singles, lesbian and gay couples, and transsexual people. Hum Reprod 2014 ; 29 : 1859-65.
PubMed
20) 中塚幹也. 性同一性障害診療を取り巻く最近の状況, 専門知識を持っておこうと思う方へ. 日本女性医学学会ニューズレター 2019 ; 24 : 10.
 
P.198 掲載の参考文献
1) Black MM, et al. Early childhood development coming of age : science through the life course. Lancet 2017 ; 389 : 77-90.
PubMed
2) Blos P. The second individuation process of adolescence. Psychoanal Study Child 1967 ; 22 : 162-86.
PubMed
3) Angold A, et al. Puberty and depression : the roles of age, pubertal status and pubertal timing. Psychol Med 1998 ; 28 : 51-61.
PubMed
4) Roberts RE, Duong HT. The prospective association between sleep deprivation and depression among adolescents. Sleep 2014 ; 37 : 239-44.
PubMed
5) Boynton-Jarrett R, et al. Childhood abuse and age at menarche. J Adolesc Health 2013 ; 52 : 241-7.
PubMed
6) Barrio CA. Assessing suicide risk in children : guidelines for developmentally appropriate interviewing. Journal of Mental Health Counseling 2007 ; 29 : 50-66.
 
7) Diamond G, et al. Attachment-based family therapy : a review of the empirical support. Fam Process 2016 ; 55 : 595-610.
PubMed
8) 小林隆児, 皿田洋子. 強迫現象とその回復過程からみた前思春期発達. 児童青年精神医学とその近接領域 1992 ; 33 : 163-76.
 
9) 中井義勝. 摂食障害治療ガイドラインについて. 心身医学 2016 ; 56 : 120-6.
Medical*Online
10) Howard LM, et al. No health without perinatal mental health. Lancet 2014 ; 384 : 1723-4.
PubMed
11) Austin MP, Marce Society Position Statement Advisory Committee. Marce International Society position statement on psychosocial assessment and depression screening in perinatal women. Best Pract Res Clin Obstet Gynaecol 2014 ; 28 : 179-87.
PubMed
12) Dennis CL, et al. Prevalence of antenatal and postnatal anxiety : systematic review and meta-analysis. Br J Psychiatry 2017 ; 210 : 315-23.
PubMed
13) Meltzer-Brody S, et al. Postpartum psychiatric disorders. Nat Rev Dis Primers 2018 ; 4 : 18022.
PubMed
14) Cook N, et al. Maternal posttraumatic stress disorder during the perinatal period and child outcomes : a systematic review. J Affec Disord 2018 ; 225 : 18-31.
 
15) Grote NK, et al. A Randomized Trial of Collaborative Care for Perinatal Depression in Socioeconomically Disadvantaged Women : the impact of comorbid posttraumatic stress disorder. J Clin Psychiatry 2016 ; 77 : 1527-37.
PubMed
16) Jablonski LJ, et al. A Nurse-Driven, Community-Based Program to Support Rural Women With Perinatal Substance Use Disorder. J Obstet Gynecol Neonatal Nurs 2018 ; 47 (Suppl) : S13.
 
17) Brockington IF, et al. Severe disorders of the mother-infant relationship : definitions and frequency. Arch Womens Ment Health 2006 ; 9 : 243-51.
PubMed
18) 鈴木利人. 周産期メンタルヘルスの薬物療法 : 10の原則. 臨床婦人科産科 2017 ; 71 : 558-64.
 
19) Stevens AWMM, et al. Risk of recurrence of mood disorders during pregnancy and the impact of medication : a systematic review. J Affect Disord 2019 ; 249 : 96-103.
PubMed
20) van Ravesteyn LM, et al. Interventions to treat mental disorders during pregnancy : a systematic review and multiple treatment meta-analysis. PLoS One 2017 ; 12 : e0173397.
PubMed
21) 日本産婦人科医会. 妊産婦メンタルヘルスケアマニュアル-産後ケアへの切れ目のない支援に向けて. 東京 : 日本産婦人科医会 ; 2017.
 
22) 木下勝之. 周産期関係者等が目指す妊産婦メンタルヘルスケア. 女性心身医学 2016 ; 21 : 236-43.
 
23) Zanjani F, et al. Memory banking : a life story intervention for aging preparation and mental health promotion. J Aging Health 2015 ; 27 : 355-76.
PubMed
P.209 掲載の参考文献
1) Nakamura K. The concept and treatment of locomotive syndrome : its acceptance and spread in Japan. J Orthop Sci 2011 ; 16 : 489-91.
PubMed
2) Iki M, et al. Cohort profile : The Japanese Population-based Osteoporosis (JPOS) Cohort Study. Int J Epidemiol 2015 ; 44 : 405-14.
PubMed
3) 骨粗鬆症の予防と治療ガイドライン作成委員会編. 骨粗鬆症の予防と治療ガイドライン 2015年版. 東京 : ライフサイエンス出版 ; 2015.
 
4) Omori G, et al. Association of mechanical factor with medial knee osteoarthritis : a cross-sectional study from Matsudai Knee Osteoarthritis Survey. J Orthop Sci 2016 ; 21 : 463-8.
PubMed
5) Yoshimura N, et al. Prevalence of knee osteoarthritis, lumber spondylosis, and osteoporosis in Japanese men and women : the research on osteoarthritis/osteoporosis against disability (ROAD) study. J Bone Miner Metab 2009 ; 27 : 620-8.
 
6) 日本整形外科学会. ロコモパンフレット 2015年度版. https://www.joa.or.jp/public/locomo/locomo_pamphlet_2015.pdf
 
7) Fried LP, et al. Cardiovascular Health Study Collaborative Research Group : frailty in older adults : evidence for a phenotype. A Biol Sci Med Sci 2001 ; 56 : 146-56.
 
8) Satake S, et al. Prevalence of frailty among community-dwellers and outpatients in Japan as defined by the Japanese version of the Cardiovascular Health Study criteria. Geriatr Gerontol Int 2017 ; 17 : 2629-34.
PubMed
9) Chen LK, et al. Sarcopenia in Asia : consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc 2014 ; 15 : 95-101.
 
P.222 掲載の参考文献
1) Emge LA, et al. Pelvic organ prolapse : four thousand years of treatment. Clin Obstet Gynecol 1966 ; 9 : 997-1032.
PubMed
2) Stromayr C. Die Handschrift des Schnitt-und Augenarztes Caspar Stromayr in Lindau im Bondensee. Berlin : Brunn ; 1925.
 
3) Goldman J, et al. The Neugebauer-Le Fort operation : a review of 118 partial colpocleises. Eur J Obstet Gynecol Reprod Biol 1981 ; 12 : 31-5.
 
4) Fothergill WE. The supports of the pelvic viscera : a review of some recent contributions to pelvic anatomy, with a clinical introduction. Proc R Soc Med 1908 ; 1 : 43-60.
PubMed
5) FDA. FDA Public Health Notification : Serious Complications Associated with Transvaginal Placement of Surgical Mesh in Repair of Pelvic Organ Prolapse and Stress Urinary Incontinence. FDA Medical Device Public Health Notifications 2008 ; Urogynecologic Surgical Mesh : Update on the Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse 2011.
 
6) DeLancey JO. Functional anatomy of the female lower urinary tract and pelvic floor. Ciba Found Symp 1990 ; 151 : 57-69.
PubMed
7) Olsen AL, et al. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997 ; 89 : 501-6.
PubMed
8) Bump RC, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996 ; 175 : 10-7.
PubMed
9) Homma Y, et al. Symptom assessment tool for overactive bladder syndrome : overactive bladder symptom score. Urology 2006 ; 68 : 318-23.
PubMed
10) Kegel AH. The nonsurgical treatment of genital relaxation : use of the perineometer as an aid in restoring anatomic and functional structure. Ann West Med Surg 1948 ; 2 : 213-6.
PubMed
11) Cody JD, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2009 ; CD001405.
 
12) Richardson AC, et al. A new look at pelvic relaxation. Am J Obstet Gynecol 1976 ; 126 : 568-73.
 
13) Fong ED, et al. Review Article : mid-urethral synthetic slings for female stress urinary incontinence. BJU Int 2010 ; 106 : 596-608.
PubMed
14) Koyama M, et al. Surgical reinforcement of support for the vagina in pelvic organ prolapse : concurrent iliococcygeus fascia colpopexy (Inmon technique). Int Urogynecol J Pelvic Floor Dysfunct 2005 ; 16 : 197-202.
 
15) Conger GT, et al. The Manchester-Fothergill operation, its place in gynecology : a review of 960 cases at University Hospitals, Iowa City, Iowa. Am J Obstet Gynecol 1958 ; 76 : 634-40.
 
16) Glavind K, et al. Colpectomy or Le Fort colpocleisis : a good option in selected elderly patients. Int Urogynecol J Pelvic Floor Dysfunct 2005 ; 16 : 48-51 ; discussion 51.
 
17) Holley RL, et al. Recurrent pelvic support defects after sacrospinous ligament fixation for vaginal vault prolapse. J Am Coll Surg 1995 ; 180 : 444-8.
PubMed
18) Debodinance P, et al. Changing attitudes on the surgical treatment of urogenital prolapse : birth of the tension-free vaginal mesh. J Gynecol Obstet Biol Reprod (Paris) 2004 ; 33 : 577-88.
 
19) Rahkola-Soisalo P, et al. Pelvic organ prolapse repair using the uphold vaginal support system : 5-year follow-up. Female Pelvic Med Reconstr Surg 2017 Dec 11.
 
20) Brown DN, et al. Surgical techniques for advanced stage pelvic organ prolapse. Minerva Ginecol 2016 ; 68 : 55-66.
PubMed
P.234 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会編. 骨粗鬆症の予防と治療ガイドライン 2015年版. 東京 : ライフサイエンス出版 ; 2015.
 
2) Hadji P, et al. Pregnancy-associated osteoporosis : a case control study. Osteopoporos Int 2017 ; 28 : 1393-9.
PubMed
3) Yoshimura N, et al. Cohort profile : research on osteoarthritis/osteoporosis against disability study. Int J Epidemiol 2010 ; 39 : 988-95.
PubMed
4) Yoshimura N, et al. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women : the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 2009 ; 27 : 620-8.
PubMed
5) Frost HM. Dynamics of bone remodeling. Bone Biodyn 1964 ; 315-33.
 
6) 日本骨代謝学会, 日本骨粗鬆症学会合同原発性骨粗鬆症診断基準改訂検討委員会. 原発性骨粗鬆症の診断基準 (2012年度改訂版). Osteoporosis Jpn 2013 ; 21 : 9-21.
Medical*Online
7) Genant HK, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993 ; 8 : 1137-48.
PubMed
8) Orito S, et al. Age-related distribution of bone and skeletal parameters in 1,322 Japanese young women. J Bone Miner Metab 2009 ; 27 : 698-704.
PubMed
9) Welten DC, et al. A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males. J Nutr 1995 ; 125 : 2802-13.
 
10) Miyabara Y, et al. Effect of physical activity and nutrition on bone mineral density in young Japanese women. J Bone Miner Metab 2007 ; 25 : 414-8.
 
11) Zhao R, et al. The effect of differing resistance training modes on the preservation of bone mineral density in postmenopausal women : a meta-analysis. Osteoporos Int 2015 ; 26 : 1605-18.
PubMed
12) Ma D, et al. Effects of walking on the preservation of bone mineral density in perimenopausal and postmenopausal women : a systematic review and meta-analysis. Menopause 2013 ; 20 : 1216-26.
PubMed
13) Gillespie LD, et al. Interventions for preventing falls in older people living in the community. Cochran Database Syst Rev 2012 ; 9 : CD007146.
PubMed
14) Cameron ID, et al. Interventions for preventing falls in older people living in care facilities and hospitals. Cochran Database Syst Rev 2012 ; 12 : CD005465.
 
15) Kanis JA, on behalf of World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. WHO Collaborating Center for Metabolic Bone Diseases. University of Sheffield ; 2007.
 
16) Rossouw JE, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 ; 288 ; 321-2.
 
17) Wells GA, et al. Alendronate for the primary and secondary prevention of osteoporotic fracture in postmenopausal women. Cochran Database Syst Rev 2008 ; 1 : CD001155.
PubMed
18) Cranney, et al. Meta-analysis of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002 ; 23 : 517-23.
PubMed
19) Cummings SR, et al. Denosumab for prevention of fracture in postmenopausal women with osteoporosis. N Engl J Med 2009 ; 361 : 756-65.
PubMed
20) Neer RM, et al. Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 ; 344 : 1434-41.
PubMed
21) Bischoff-Ferrari HA, et al. Effect of vitamin D on falls : a meta-analysis of randomized controlled study. JAMA 2004 ; 291 : 1999-2006.
 

4章 女性ヘルスケアに関連する課題と対応

P.245 掲載の参考文献
1) 上田一雄. 循環器疾患の危険因子-本邦における特徴とその変遷. 日循協誌 1994 ; 29 : 57-67.
 
2) Kinjo K, et al, COSMO Group. An epidemiological analysis of cardiovascular diseases in Okinawa, Japan. Hypertens Res 1992 ; 15 : 111-9.
 
3) Kodama K, et al. Trend of coronary heart disease and its relationship to risk factors in a Japanesepopulation : a 26-year follow-up, Hiroshima/Nagasaki study. Jpn Circ J 1990 ; 54 : 414-21.
 
4) Yoshida M, et al. Incidence of acute myocardial infarction in Takashima, Shiga, Japan. Circ J 2005 ; 69 : 404-8.
PubMed
5) NIPPON DATA 80 Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J 2006 ; 70 : 1249-55.
 
6) Kannel WB, et al. Menopause and risk of cardiovascular disease. The Framingham study. Ann Intern Med 1976 ; 85 : 447-52.
PubMed
7) Kosuge M, et al, Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Sex differences in early mortality of patients undergoing primary stenting for acute myocardial infarction. Circ J 2006 ; 70 : 217-21.
PubMed
8) Vakili BA, et al. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation 2001 ; 104 : 3034-8.
PubMed
9) Kudenchuk PJ, et al. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Caridol 1996 ; 78 : 9-14.
 
10) Chandra NC, et al. Observations of the treatment of women in the United States with myocardial infarction : a report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1998 : 158 : 981-8.
 
11) Marso SP, et al. Improving in-hospital mortality in the setting of an increasing risk profile among patients undergoing catheter-based reperfusion for an acute myocardial infarction without cardiogenic shock. J Invasive Cardiol 2003 ; 15 : 711-6.
PubMed
12) Kimura Y, et al. Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. Intern Med 1998 ; 37 : 736-45.
PubMed
13) 日本動脈硬化学会編. 動脈硬化性疾患予防ガイドライン 2017年版. 東京 : 日本動脈硬化学会 ; 2017.
 
14) Imamura T, et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population : the Hisayama study. Stroke 2009 ; 40 : 382-8.
 
15) Noda H, et al. Gender difference of association between LDL cholesterol concentrations and mortality from coronary heart disease amongst Japanese : the Ibaraki Prefectural Health Study. J Intern Med 2010 ; 267 : 576-87.
PubMed
16) Okamura T. Dyslipidemia and cardiovascular disease : a series of epidemiologic studies in Japanese populations. J Epidemiol 2010 ; 20 : 259-65.
PubMed
17) Imano H, et al. Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women : The Circulatory Risk in Communities Study (CIRCS). Prev Med 2011 ; 52 : 381-6.
PubMed
18) Ikenoue N, et al. Small low-density lipoprotein particles in women with natural or surgically induced menopause. Obstet Gynecol 1999 ; 93 : 566-70.
PubMed
19) Arca M, et al. Hypercholesterolemia in postmenopausal women : metabolic defects and response to low-dose lovastatin. JAMA 1994 ; 271 : 453-9.
PubMed
20) Wakatsuki A, et al. Lipoprotein metabolism in postmenopausal and oophorectomized women. Obstet Gynecol 1995 ; 85 : 523-8.
PubMed
21) Nigon F, et al. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991 ; 32 : 1741-53.
PubMed
22) Tribble DL, et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992 ; 93 : 189-99.
PubMed
23) Wakatsuki A, et al. Small low-density lipoprotein particles and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis 2004 ; 177 : 329-36.
PubMed
24) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002 ; 288 : 321-33.
 
25) Hsia J, et al, Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease : the Women's Health Initiative. Arch Intern Med 2006 ; 166 : 357-65.
PubMed
26) Wakatsuki A, et al. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002 ; 106 : 1771-6.
PubMed
27) Nii S, et al. Hepatic effects of estrogen on plasma distribution of small dense low-density lipoprotein and free radical production in postmenopausal women. J Atheroscler Thromb 2016 ; 23 : 810-8.
PubMed
28) Wakatsuki A, et al. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. Arterioscler Thromb Vasc Biol 2003 ; 23 : 1948-9.
PubMed
29) Lokkegaard E, et al. Hormone therapy and risk of myocardial infarction : a national register study. Eur Heart J 2008 ; 29 : 2660-8.
PubMed
30) Wakatsuki A, et al. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001 ; 104 : 1773-8.
PubMed
31) Nakamura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomized controlled trial. Lancet 2006 ; 368 : 1155-63.
PubMed
32) 日本女性医学学会編. 女性の動脈硬化性疾患発症予防のための管理指針 2018年度版. 東京 : 日本女性医学学会 ; 2018.
 
33) Kawano H, et al, Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Sex differences of risk factors for acute myocardial infarction in Japanese patients. Circ J 2006 ; 70 : 513-7.
PubMed
34) NIPPON DATA 80 Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J 2006 ; 70 : 1249-55.
 
35) Bonds DE, et al. The effect of conjugated equine oestrogen on diabetes incidence : the Women's Health Initiative randomised trial. Diabetologia 2006 ; 49 : 459-68.
PubMed
36) Salpeter SR, et al. Meta-analysis : effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006 ; 8 : 538-54.
PubMed
37) Howard BV, et al. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004 ; 110 : 201-6.
PubMed
P.253 掲載の参考文献
1) 辻卓夫. 皮膚の老化と女性ホルモン. 皮膚病診療 2001 ; 6 : 552-6.
 
2) 溝口昌子ほか. 中高年女性の皮膚とホルモン補充療法. 香粧会誌 2001 ; 25 : 211-6.
 
3) 南光弘子. 月経疹, ピルによる皮膚病変. MB Derma 2006 ; 119 : 8-15.
 
4) 船坂陽子. ケミカルピーリングの疾患別治療プログラム しみ. 松永佳世子ほか編. 皮膚科診療プラクティスシリーズ 11巻 ケミカルピーリングとコラーゲン注射の実際-美容皮膚科最前線. 東京 : 文光堂 ; 2001. p.112-21.
 
5) 船坂陽子. 肝斑. 鈴木啓之, 神崎保編. 皮膚科診療カラーアトラス体系 3色調異常/水疱性疾患/膿疱症. 東京 : 講談社 ; 2009. p.50-3.
 
6) Kang WH, et al. Melasma : histopathological characteristics in 56 Korean patients. Br J Dermatol 2002 ; 146 : 228-37.
PubMed
7) Sanchez NP, et al. Melasma : a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermaol 1981 ; 4 : 698-710.
PubMed
8) Kang HY, et al. The dermal stem cell factor and c-kit are overexpressed in melasma. Br J Dermatol 2006 ; 154 : 1094-9.
 
9) Kim EH, et al. The vascular characteristics of melasma. J Dermatol Sci 2007 ; 46 : 111-6.
PubMed
10) Jang YH, et al. Oestrogen and progesterone receptor expression in melasma : an immunohistochemical analysis. J Eur Acad Dermatol Venereol 2010 ; 24 : 1312-6.
PubMed
11) Lee DJ, et al. Defective barrier function in melasma skin. J Eur Acad Dermatol Venereol 2012 ; 26 : 1533-7.
PubMed
12) 船坂陽子. 肝斑の治療法-海外でのEBMからの検証. Aesthetic Dermatol 2010 ; 20 : 321-8.
 
13) Mizoguchi M, et al. Clinical, pathological, and etiologic aspects of acquired dermal melanocytosis. Pigment Cell Res 1997 ; 10 : 176-83.
PubMed
P.263 掲載の参考文献
1) Gumbiner CH. Precordial catch syndrome. South Med J 2003 ; 96 : 38-41.
PubMed
2) Tanaka H, et al. Analysis of pregnancies in women with Takayasu arteritis : complication of Takayasu arteritis involving obstetric or cardiovascular events. J Obstet Gynaecol Res 2014 ; 40 : 2031-6.
PubMed
3) Thomas E, et al. Pulmonary hypertension and pregnancy outcomes : insights from the national inpatient sample. J Am Heart Assoc 2017 ; 6 : e006144.
 
4) Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation 2016 ; 133 : 1397-409.
PubMed
5) Halkein J, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013 ; 123 : 2143-54.
PubMed
6) Bajou K, et al. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat Med 2014 ; 20 : 741-7.
PubMed
7) Hilfiker-Kleiner D, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007 ; 50 : 2354-6.
PubMed
8) 循環器病の診断と治療に関するガイドライン (2008-2009年度合同研究班報告). 循環器領域における性差医療に関するガイドライン. Cir J 2010 ; 74 Suppl II : 1085-160.
 
9) Graf S, et al. Typical chest pain and normal coronary angiogram : cardiac risk factor analysis versus PET for detection of microvascular disease. J Nucl Med 2007 ; 48 : 175-81.
 
10) Lanza GA, et al. Relation between stress-induced myocardial perfusion defects on cardiovascular magnetic resonance and coronary microvascular dysfunction in patients with cardiac syndrome X. J Am Coll Cardiol 2008 ; 51 : 466-72.
PubMed
11) Johnson BD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease : results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004 ; 109 : 2993-9.
PubMed
12) Takii T, et al. Trends in acute myocardial infarction incidence and mortality over 30 years in Japan : report from the MIYAGI-AMI Registry Study. Circ J 2010 ; 74 : 93-100.
PubMed
13) Stampfer MJ, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000 ; 343 : 16-22.
PubMed
14) Sato M. Takotsubo-type cardiomyopathy due to multivessel spasm. In : Kodama K, et al, editors. Clinical Aspect of Myocardial Injury : From Ischemia to Heart Failure. Kagakuhyouronsha ; 1990. p.56-64.
 
15) Lyon AR, et al. Stress (Takotsubo) cardiomyopathy : a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008 ; 5 : 22-9.
PubMed
16) 日本循環器学会/日本高血圧学会/日本心臓病学会合同ガイドライン (2012-2013年度合同研究班報告). 2014年版 災害時循環器疾患の予防・管理に関するガイドライン. http://www.jpnsh.jp/Disaster/guidelineall.pdf
 
17) O'Meara E, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure : results of the Candesartan in Heart failure : Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007 ; 115 : 3111-20.
 
18) 合同研究班参加学会. 2015-2016年度活動 成人先天性心疾患診療ガイドライン (2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_ichida_h.pdf
 
19) Silversides CK, et al. Pregnancy outcomes in women with heart disease, the CARPREG II Study. J Am Coll Cardiol 2018 ; 71 : 2419-30.
PubMed
20) Drenthen W, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010 ; 31 : 2124-32.
PubMed
21) 日本循環器学会, 日本産科婦人科学会. 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2018年改訂版).
 
22) 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告). 川崎病心臓血管後遺症の診断と治療に関するガイドライン (2013年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2013_ogawas_d.pdf
 
P.273 掲載の参考文献
1) Papanicolaou GN, et al. The diagnostic value of smears in carcinoma of the uterus. Am J Obstet Gynecol 1941 ; 42 : 193-206.
 
2) 日本産婦人科医会. ベセスダシステム 2001 準拠子宮頸部細胞診報告様式の理解のために. 2008.
 
3) Aklimunnessa K, et al. Effectiveness of cervical cancer screening over cervical cancer mortality among Japanese women. Jpn J Clin Oncol 2006 ; 36 : 511-8.
PubMed
4) Ronco G, et al. Impact of the introduction of organized screening for cervical cancer in Turin, Italy : cancer incidence by screening history 1992-98. Br J Cancer 2005 ; 93 : 376-8.
PubMed
5) Laara E, et al. Trends in mortality from cervical cancer in the Nordic countries : association with organised screening programmes. Lancet 1987 ; 1 : 1247-9.
PubMed
6) Sigurdsson K, et al. Effectiveness of cervical cancer screening in Iceland, 1964-2002 : a study on trends in incidence and mortality and the effect of risk factors. Acta Obstet Gynecol Scand 2006 ; 85 : 343-9.
 
7) Arbyn M, et al. Liquid compared with conventional cervical cytology : a systematic review and meta-analysis. Obstet Gynecol 2008 ; 111 : 167-77.
PubMed
8) Strander B, et al. Liquid-based cytology versus conventional Papanicolaou smear in an organized screening program : a prospective randomized study. Cancer 2007 ; 111 : 285-91.
 
9) Rozemeijer K, et al. Comparing SurePath, Thin-Prep, and conventional cytology as primary test method : SurePath is associated with increased CIN II + detection rates. Cancer Causes Control 2016 ; 27 : 15-25.
 
10) Klug SJ, et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. Int J Cancer 2013 ; 132 : 2849-57.
PubMed
11) Siebers AG, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors : a randomized controlled trial. JAMA 2009 ; 302 : 1757-64.
PubMed
12) Mayrand MH, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007 ; 357 : 1579-88.
PubMed
13) Koilopoulos G, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017 ; 8 : CD008587.
PubMed
14) Kurokawa T, et al. The ideal strategy for cervical cancer in Japan : result from the Fukui Cervical Cancer Screening Study. Cytopathology 2018 ; 29 : 361-7.
PubMed
15) Naucler P, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007 ; 357 : 1589-97.
PubMed
16) Ronco G, et al, New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia : a randomised controlled trial. Lancet Oncol 2010 ; 11 : 249-57.
 
17) Rijkaart DC, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer : final results of the POBSCAM randomised controlled trial. Lancet Oncol 2012 ; 13 : 78-88.
PubMed
18) Kitchener HC, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC) : a randomised controlled trial. Lancet Oncol 2009 ; 10 : 672-82.
PubMed
19) Ronco G, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer : follow-up of four European randomised controlled trials. Lancet 2014 ; 383 : 524-32.
PubMed
20) Leinonen MK, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing : prospective randomised trial in Finland. BMJ 2012 ; 345 : e7789.
PubMed
21) Canfell K, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination : results of the Compass pilot randomised trial. PLoS Med 2017 ; 14 : e1002388.
 
22) Ogilvie GS, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months. The HPV FOCAL randomized clinical trial. JAMA 2018 ; 320 : 43-52.
PubMed
23) Schiffman M, et al. Relative performance of HPV and cytology components of contesting in cervical cancer screening. J Natl Cancer Inst 2018 ; 110 : 501-8.
 
24) Quinn M, et al. Effect of screening on incidence of and mortality from cancer of cervix in England : evaluation based on routinely collected statistics. BMJ 1999 ; 318 : 904-8.
PubMed
25) Verdoodt F, et al. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits : a systematic review and meta-analysis of randomised trials. Eur J Cancer 2015 ; 51 : 2375-85.
 
26) Arbyn M, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples : a meta-analysis. Lancet Oncol 2014 ; 15 : 172-83.
PubMed
27) Pathak N, et al. Accuracy of urinary human papillomavirus testing for presence of cervical HPV : systematic review and meta-analysis. BMJ 2014 ; 349 : g5264.
PubMed
28) The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 ; 356 : 1915-27.
 
29) Paavonen J, et al, HPV PATRICIA study group. Efficacy of human papillomavirus (HPV) -16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA) : final analysis of a double-blind, randomized study in young women. Lancet 2009 ; 374 : 301-14.
 
30) Dobson SR, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women : a randomized clinical trial. JAMA 2013 ; 309 : 1793-802.
PubMed
31) D'Addario M, et al. Two-dose schedules for human papillomavirus vaccine : systematic review and meta-analysis. Vaccine 2017 ; 35 : 2892-901.
PubMed
32) Arrossi S, et al. Primary Prevention of Cervical Cancer : American Society of Clinical Oncology Resource-Stratified Guideline. J Glob Oncol 2017 ; 3 : 611-34.
 
33) Human papillomavirus vaccines : WHO position paper, May 2017. Wkly Epidemiol Rec 2017 ; 92 : 241-68.
PubMed
34) Viscidi RP, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection : results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004 ; 13 : 324-7.
PubMed
35) Naud PS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine : final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014 ; 10 : 2147-62.
PubMed
36) Nygard M, et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol 2015 ; 22 : 943-8.
 
37) Olsson SE, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009 ; 5 : 696-704.
PubMed
38) Garland SM, et al, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 ; 356 : 1928-43.
PubMed
39) Hildesheim A, et al, CVT Group. Efficacy of the HPV-16/18 vaccine : final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014 ; 32 : 5087-97.
PubMed
40) Castellsague X, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6,11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011 ; 105 : 28-37.
PubMed
41) Schwarz TF, et al, HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009 ; 27 : 581-7.
 
42) Wheeler CM, et al, HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012 ; 13 : 100-10.
 
43) Herrero R, et al, Costa Rica Vaccine Trial Group. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine : a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011 ; 1 : 408-19.
PubMed
44) Brown DR, et al. The impact of quadrivalent human papillomavirus (HPV ; types 6, 11, 16, and 18) L1virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009 ; 199 : 926-35.
 
45) GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV) -16/18 AS04-adjuvanted vaccine : analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009 ; 374 : 1975-85.
 
46) Arbyn M, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018 ; 5 : CD009069.
PubMed
47) Huh WK, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years : a randomised, double-blind trial. Lancet 2017 ; 390 : 2143-59.
 
48) Ali H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013 ; 13 : 140.
PubMed
49) Read TR, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011 ; 87 : 544-7.
PubMed
50) Brotherton JM, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia : an ecological study. Lancet 2011 ; 377 : 2085-92
 
51) Gertig DM, et al. Impact of a population-based HPV vaccination program on cervical abnormalities : a data linkage study. BMC Med 2013 ; 11 : 227.
PubMed
52) Berenson AB, et al. Change in human papillomavirus prevalence among U. S. women aged 18-59 years, 2009-2014. Obstet Gynecol 2017 ; 130 : 693-701.
PubMed
53) Baldur-Felskov B, et al. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014 ; 25 : 915-22.
PubMed
54) Luostarinen T, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer 2018 ; 142 : 2186-7.
PubMed
55) Hanley SJ, et al. HPV vaccination crisis in Japan. Lancet 2015 ; 385 : 2571.
PubMed
56) Ozawa N, et al. Beneficial effects of human papillomavirus vaccine for prevention of cervical abnormalities in Miyagi, Japan. Tohoku J Exp Med 2016 ; 240 : 147-51.
PubMed
57) Konno R, et al. Effectiveness of HPV vaccination against high grade cervical lesions in Japan. Vaccine 2018 ; 36 : 7913-5.
PubMed
58) Tanaka H, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res 2017 ; 43 : 1597-601.
PubMed
59) Matsumoto K, et al. Early impact of the Japanese immunization program implemented before the HPV vaccination crisis. Int J Cancer 2017 ; 141 : 1704-6.
PubMed
60) Kudo R, et al. Bivalent human papillomavirus vaccine effectiveness in a Japanese population : high vaccine-type-specific effectiveness and evidence of cross-protection. J Infect Dis 2019 ; 219 : 382-90.
 
61) Arana JE, et al. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. Vaccine 2018 ; 36 : 1781-8.
PubMed
62) 厚生労働省. 厚生科学審議会 (予防接種・ワクチン分科会 副反応検討部会). https://www.mhlw.go.jp/stf/shingi/shingi-kousei_284075.html
 
63) Suzuki S, et al. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women : results of the Nagoya study. Papillomavirus Res 2018 ; 5 : 96-103.
PubMed
64) 日本産婦人科医会がん対策委員会. 子宮頸がん検診リコメンデーション-HPV-DNA併用検診にむけて. 2011.
 
65) Kim JJ, et al. Optimal cervical cancer screening in women vaccinated against human papillomavirus. J Natl Cancer Inst 2016 ; 109 : djw216.
PubMed
P.289 掲載の参考文献
1) 内閣府男女共同参画局. 男女間における暴力に関する調査報告書. 平成30年3月.
 
2) 内閣府. 性犯罪・性暴力被害者のためのワンストップ支援センター (一覧). http://www.gender.go.jp/policy/no_violence/avjk/pdf/one_stop.pdf
 
3) World Health Organization. Guidelines for medico-legal care of victims of sexual violence. Geneva : World Health Organization ; 2003. ISBN 92-4-154628-X
 
4) Kessler RC, et al. Trauma and PTSD in the WHO World Mental Health Surveys. Eur J Psychotraumatol 2017 ; 8 : 1353383.
PubMed
5) 警察庁生活安全局生活安全企画課・刑事局捜査第一課. 平成29年におけるストーカー事案及び配偶者からの暴力事案等への対応状況について. 平成30年3月15日.
 
6) WHO guidelines approved by the guidelines review committee. Responding to Intimate Partner Violence and Sexual Violence Against Women : WHO Clinical and Policy Guidelines. WHO ; 2013.
 
7) Adams JA, et al. Updated guidelines for the medical assessment and care of children who may have been sexually abused. J Pediatr Adolesc Gynecol 2016 ; 29 : 81-7.
PubMed
8) Berkoff MC, et al. Has this prepubertal girl been sexually abused? JAMA 2008 ; 300 : 2779-92.
PubMed
P.301 掲載の参考文献
1) 森良一. 学校における性に関する指導について (学習指導要領に基づいて). https://www.mhlw.go.jp/stf/shingi/2r9852000001dh87-att/2r9852000001dhhq.pdf (最終閲覧日2019年6月21日)
 
2) 現代高等保健体育 (50・大修館・保体 304). 東京 : 大修館書店 ; 2017.
 
3) 現代高等保健体育 (改訂版) 教授用参考資料 (保体 304). 東京 : 大修館書店 ; 2017. p.205-51.
 
4) 文部科学省. 中学校学習指導要領 (平成29年告示) 解説 総則編. http://www.mext.go.jp/component/a_menu/education/micro_detail/__icsFiles/afieldfile/2019/03/18/1387018_001.pdf (最終閲覧日2019年6月21日)
 
5) 北村邦夫. I 性教育はどうして必要なんだろう? Q2 中高校生・10代の人工妊娠中絶, 出産, 性感染症の現状は? 浅井春夫ほか編著. 性教育はどうして必要なんだろう? 包括的性教育をすすめるための50のQ&A. 東京 : 大月書店 ; 2018. p.23-32.
 
6) 日本家族計画協会. 第8回男女の生活と意識に関する調査報告. 東京 : 日本家族協会 ; 2017. p.170.
 
7) 北村邦夫. カラーグラフ 性教育について, 医療従事者として何ができるか. 小児看護 2018 ; 41 : 1358-64.
 
8) 日本産婦人科医会. 思春期ってなんだろう? 性ってなんだろう? (2019年度改訂版). http://www.jaog.or.jp/about/project/document/shisyunnkibunnkatsu/ (最終閲覧日2019年6月21日)
 
9) UNAIDS, UNFPA, UNICEF, UNWOMEN, WHO. Revises edition. International Technical Guidance on Sexuality Education : An Evidence-informed Approach. http://unesdoc.unesco.org/images/0026/002607/260770e.pdf (最終閲覧日2019年6月21日)
 
10) UNESCO編, 浅井春夫ほか訳. 国際セクシュアリティ教育ガイダンス. 東京 : 明石書店 ; 2017. p.213.
 

5章 乳腺疾患

P.308 掲載の参考文献
1) Eberl MM, et al. Characterizing breast symptoms in family practice. Ann Fam Med 2008 ; 6 : 528-33. PMID : 19001305
 
2) 国立がん情報センター. がん情報サービス, がん登録・統計. http://gdb.ganjoho.jp/graph_db/index (2019年6月29日アクセス)
 
3) Hughes LE, et al. Aberrations of normal development and involution (ANDI) : a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 1987 ; 2 : 1316-9.
 
4) 坂元吾偉監修. 乳腺症の組織像. 乳腺症の臨床-その概念と診療のためのアトラス. 東京 : 篠原出版新社 ; 1997. p.44-51.
 
5) 秋山太, 坂元吾偉. 乳腺症の病理診断の現状. 癌の臨床 1997 ; 43 : 6-10.
Medical*Online
6) Krings G, et al. Fibroepithelial lesions ; The WHO spectrum. Semin Diagn Pathol 2017 ; 34 : 438-52.
PubMed
7) Tan PH, et al. Fibroepithelial tumours. In : Lakhani SR, et al, eds. WHO Classification of Tumours of the Breast. 4th ed. Lyon, France : International Agency for Research on Cancer (IARC) 2012. p.141-7.
 
8) Spitaleri G, et al. Breast phyllodes tumor : a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol 2013 ; 88 : 427-36.
 
9) Fitzgibbons PL, et al. Benign breast changes and the risk for subsequent breast cancer : an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998 ; 122 : 1053-5.
PubMed
10) Dyrstad SW, et al. Breast cancer risk associated with benign breast disease : systematic review and meta-analysis. Breast Cancer Res Treat 2015 ; 149 : 569-75.
PubMed
11) Gierisch JM, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers : a systematic review. Cancer Epidemiol Biomarkers Prev 2013 ; 22 : 1931-43.
PubMed
12) Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 ; 288 : 321-33.
 
13) Canny PF, et al. Fibroadenoma and the use of exogenous hormones : a case-control study. Am J Epidemiol 1988 ; 127 : 454-61.
PubMed
14) Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 1999 ; 82 : 191-6.
PubMed
15) Harvey JA. Use and cost of breast imaging for postmenopausal women undergoing hormone replacement therapy. AJR Am J Roentgenol 1999 ; 172 : 1615-9.
PubMed
P.315 掲載の参考文献
1) 日本乳癌学会編. 臨床・病理 乳癌取扱い規約. 第18版. 東京 : 金原出版 ; 2018
 
2) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985 ; 1 : 836-40.
PubMed
3) Howell A, et al, ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 ; 365 : 60-2.
PubMed
日本乳癌学会編. 乳癌診療ガイドライン 1 治療編. 東京 : 金原出版 ; 2018.
 
NCCNガイドライン日本語版. https://www2.trikobe.org/nccn/guideline/index.html
 
ASCOガイドライン. https://www.asco.org/practice-guidelines
 
P.327 掲載の参考文献
1) 国立がん研究センターがん対策情報センター. https://ganjoho.jp/public/index.html
 
2) 乳房健康研究会. I. 一般女性意識行動調査. 乳がん検診に関する調査 2013. https://breastcare.jp/pdf/2013_report1.pdf
 
3) 斉藤博 (主任研究者). 有効性評価に基づく乳がん検診ガイドライン 2013年度版. 国立がん研究センター, がん予防・検診研究センター ; 2014.
 
4) Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening : an independent review. Lancet 2012 ; 380 : 1778-86.
PubMed
5) U. S. Preventive Service Task Force. Breast cancer screening. Released Date : Janualy 2016.
 
6) Oeffinger KC, et al. Breast cancer screening for women at average risk 2015 guideline update from the American Cancer Society. JAMA 2015 ; 314 : 1599-614.
PubMed
7) 日本乳癌学会編. 乳癌診療ガイドライン 2 疫学・診断編 2018年版. 東京 : 金原出版 ; 2018.
 
8) 日本産科婦人科学会, 日本産婦人科医会編・監. 産婦人科診療ガイドライン-婦人科外来編 2017. 東京 : 日本産科婦人科学会 ; 2017.
 
9) Kolb TM, et al. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them : an analysis of 27825 patient evaluations. Radiology 2002 ; 225 : 165-75.
 
10) Ohuchi N, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START) : a randomized controlled trial. Lancet 2016 ; 387 : 341-8.
 
11) 日本乳癌検診学会超音波検診精度管理委員会編. 超音波による乳がん検診の手引き-制度管理マニュアル. 東京 : 南江堂 ; 2016.
 
12) 日本乳癌検診学会総合判定委員会編. マンモグラフィと超音波検査の総合判定マニュアル. 東京 : 篠原出版新社 ; 2015.
 
13) 日本医学放射線学会, 日本放射線技術学会編. マンモグラフィガイドライン. 第3版増補版. 東京 : 医学書院 ; 2014.
 
14) 日本乳腺甲状腺超音波医学会編. 乳房超音波診断ガイドライン. 改訂第3版. 東京 : 南江堂 ; 2014.
 
15) Wang M, et al. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions : a systematic review and meta-analysis. Breast 2017 ; 31 : 157-66.
 
16) Bundred SM, et al. Randomized controlled trial of stereotactic 11-G vacuum-assisted core biopsy for the diagnosis and management of mammographic microcalcification. Br J Radiol 2016 ; 89 : 20150504.
PubMed
17) 厚生労働省. 若年乳がん患者のサバイバーシップ支援プログラム, 若年乳がん. http://www.jakunen.com/html/tokucho/yogo/html
 
18) 加藤栄一ほか. 妊娠関連乳癌27例, 非妊娠関連乳癌90例, 妊娠期乳房超音波検査426例の検討-妊娠関連乳癌の早期発見を目指して. 産婦人科の実際 2019 ; 68 : 423-8.
 
19) 木村道夫, 平川久. 妊娠授乳期乳癌. 日乳癌検診学会誌 2001 ; 10 : 43-9.
 
P.337 掲載の参考文献
1) 日本乳癌学会編. 臨床・病理 乳癌取扱い規約. 第18版. 東京 : 金原出版 ; 2018.
 
2) Moran MS, et al, Society of Surgical Oncology, American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014 ; 32 : 1507-15.
PubMed
3) Houssami N, et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy : a meta-analysis. Ann Surg Oncol 2014 ; 21 : 717-30.
PubMed
4) Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis : a randomized clinical trial. JAMA 2011 ; 305 : 569-75.
PubMed
5) Donker M, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS) : a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014 ; 15 : 1303-10.
 
6) Galimberti V, et al, International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01) : a phase 3 randomised controlled trial. Lancet Oncol 2013 ; 14 : 297-305.
 
7) 日本乳癌学会編. 乳癌診療ガイドライン 1 治療編 2018年版. 第4版. 東京 : 金原出版 ; 2018.
 
8) National Comprehensive Cancer Network. NCCNガイドライン. 第8版. http://202.70.140.4/nccn/guideline/breast/index.html
 
9) Sparano JA, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015 ; 373 : 2005-14.
PubMed
10) Cardoso F, et al, MINDACT Investigators. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016 ; 375 : 717-29. doi : 10.1056/NEJMoa1602253.
 
11) Yamauchi H, et al. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound : findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan. Breast Cancer Res Treat 2018 ; 172 : 679-87.
PubMed
12) Isakoff SJ, et al. TBCRC009 : a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015 ; 33 : 1902-9.
PubMed
13) Japan Breast Cancer Research Group. JBCRG-22 (Neo Entrance) 医師主導治験. Triple negative乳癌における, エリブリンメシル酸塩を用いた術前化学療法多施設共同無作為化第II相臨床試験. http://www.jbcrg.jp/clinicaltrials/detail.php?id=54
 
14) Schmid P, et al, IMpassion 130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018 ; 379 : 2108-21.
 
15) Baselga J, et al, CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012 ; 366 : 109-19.
 
16) Swain SM, et al, CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015 ; 372 : 724-34.
 
17) Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere) : a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012 ; 13 : 25-32.
PubMed
18) von Minckwitz G, et al, APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017 ; 377 : 122-31.
 
19) von Minckwitz G, et al, KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019 ; 30 : 617-28. doi : 10.1056/NEJMoa1814017. [Epub ahead of print].
 
20) Smith IC, et al. Neoadjuvant chemotherapy in breast cancer : significantly enhanced response with docetaxel. J Clin Oncol 2002 ; 20 : 1456-66.
PubMed
21) Clarke M, et al, Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival : an overview of the randomised trials. Lancet 2005 ; 366 : 2087-106.
 
22) Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer : meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018 ; 19 : 27-39.
 
23) El Hage Chehade H, et al. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg 2016 ; 212 : 969-81.
PubMed
24) Masuda N, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017 ; 376 : 2147-59.
PubMed
25) Japan Breast Cancer Research Group. OlympiA試験. 十分な局所性治療及び術前補助療法又は術後補助療法を終了した高リスク生殖細胞系BRCA1/2変異陽性HER2陰性原発乳癌患者に対する術後補助療法としてのオラパリブの有効性と安全性を評価する無作為化二重盲検並行群間比較プラセボ対照多施設共同第III相試験. http://www.jbcrg.jp/clinicaltrials/detail.php?id=47
 
26) Halpern N, et al. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. Int J Cancer 2017 ; 140 : 2145-9.
PubMed
27) Oktay K, et al. Fertility preservation in patients with cancer : ASCO Clinical Practice Guideline Update. J Clin Oncol 2018 ; 36 : 1994-2001.
PubMed
28) Lambertini M, et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst 2018 ; 110 : 426-9.
PubMed
29) Japan Breast Cancer Research Group. JBCRG-23 (POSITIVE試験). 妊娠を希望するホルモン療法感受性乳癌の若年女性における妊娠転帰及びホルモン療法中断の安全性を評価する試験. http://www.jbcrg.jp/clinicaltrials/detail.php?id=46
 

6章 女性ヘルスケアと遺伝性疾患

P.348 掲載の参考文献
1) Lu KH. Hereditary gynecologic cancers : differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 2008 ; 7 : 53-8.
PubMed
2) Miki Y, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994 ; 266 : 66-71.
 
3) Mavaddat N, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers : results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012 ; 21 : 134-47.
 
4) Kuchenbaecker KB, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017 ; 317 : 2402-16.
PubMed
5) NCCN Guidelines(R) Genetic/Familial High-Risk Assessment : Breast and Ovarian. ver 2. 2019.
 
6) Couch FJ, et al. Two decades after BRCA : setting paradigms in personalized cancer care and prevention. Science 2014 ; 343 : 1466-70.
PubMed
7) Rebbeck TR, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015 ; 313 : 1347-61.
PubMed
8) Norquist BM, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016 ; 2 : 482-90.
PubMed
9) GeneReviews(R) https://www.ncbi.nlm.nih.gov/books/NBK1247/
 
10) Boyd J, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000 ; 283 : 2260-5.
PubMed
11) Bolton KL, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012 ; 307 : 382-90.
PubMed
12) Ledermann J, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014 ; 15 : 852-61.
 
13) Pujade-Lauraine E, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21) : a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017 ; 18 : 1274-84.
 
14) McLaughlin JR, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations : a case-control study. Lancet Oncol 2007 ; 8 : 26-34.
 
15) Finch AP, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014 ; 32 : 1547-53.
PubMed
16) Cohen SA, Leininger A. The genetic basis of Lynch syndrome and its implications for clinical practice and risk management. Appl Clin Genet 2014 ; 7 : 147-58.
PubMed
17) Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003 ; 348 : 919-32.
PubMed
18) de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer 2005 ; 4 : 233-7.
PubMed
19) 大腸癌研究会編. 遺伝性大腸癌診療ガイドライン 2016年版. 東京 : 金原出版 ; 2016.
 
20) Stoffel E, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009 ; 137 : 1621-7.
PubMed
21) Koornstra JJ, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009 ; 10 : 400-8.
PubMed
22) Lynch HT, et al. Hereditary ovarian carcinoma : heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009 ; 3 : 97-137.
PubMed
23) Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 2000 ; 18 : 81S-92S.
PubMed
24) Umar A, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004 ; 96 : 261-8.
PubMed
25) Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008 ; 10 : 293-300.
PubMed
P.364 掲載の参考文献
1) 日本医学会. 医療における遺伝学的検査・診断に関するガイドライン. 2011. http://jams.med.or.jp/guideline/genetics-diagnosis.pdf
 
2) 福嶋義光. 遺伝専門医の行う遺伝カウンセリング. 東京 : 金原出版 ; 2000. p.130-7.
 
3) 松田一郎監, 福嶋義光編. 遺伝医学における倫理的諸問題の再検討 (WHO/HGN/ETH/00.4). 松本 : 信州大学医学部社会予防医学講座 ; 2002.
 
4) 小杉眞司編著. 遺伝カウンセリングのためのコミュニケーション論. 大阪 : メディカル ドゥ ; 2016. p.26-54.
 
5) がんの統計編集委員会. がんの統計 (2017年版). 2018. p.34.
 
6) Antoniou AC, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014 ; 371 : 497-506.
PubMed
7) Bennett RL, et al. Standardized human pedigree nomenclature : update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns 2008 ; 17 : 424-33.
PubMed
8) Robson ME, et al. American Society of Clinical Oncology Polycy Statement update : Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 2015 ; 22 : 3660-7.
 
9) Arai M. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer : first report after establishment of HBOC registration system in Japan. J Hum Genet 2018 ; 63 : 447-57.
PubMed
10) http://www.kohbra.kr/KOHCal/BRCA.html
 
11) 日本人類遺伝学会. 第24回遺伝医学セミナー模擬試験問題. 2014.
 
12) 岡村仁. サイコオンコロジー総論. 心身医学 2013 ; 53 : 386-91.
Medical*Online
13) Lerman C, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. JAMA 1996 ; 275 : 1885-92.
PubMed
14) Wagner TM, et al. Attitude towards prophylactic surgery and effects of genetic counseling in families with BRCA mutations. Austrian hereditary Breast and Ovarian Cancer Group. Br J Cancer 2000 ; 82 : 1249-53.
PubMed
15) Bosch N, et al. What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure? Breast 2012 ; 21 : 755-60.
PubMed
16) Nelson HD. Risk Assesment, Genetic Counselling, and Genetic Testing for BRCA-Related Cancer : Systematic Review to Update the U. A. Preventine Services Task Force Recommendation. [Internet]. 2013.
 
17) Murakami Y, et al. Psychologic distress after disclosure of genetic test results regarding hereditary nonpolyposis colorectal carcinoma. Cancer 2004 ; 101 : 395-403.
PubMed
18) 日本乳癌学会編. 遺伝性乳癌と遺伝学的検査, 遺伝カウンセリング. 乳癌診療ガイドライン 2018年版 (2) 疫学・診断編. 東京 : 金原出版 ; 2018. p.98-109.
 
19) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Geteic/Familial High-Risk Assessment : Breast and Ovarian. Ver 3. 2019.
 
20) Mutch D, et al. Hereditary gynecologic cancer. Int J Gynecol Obstet 2014 ; 124 : 189-92.
 
21) 日本HBOCコンソーシアム. かんたんチェック. http://hboc.jp/downloads/kantancheck.pdf
 
22) 新井正美. 産婦人科臨床遺伝の最前線 腫瘍分野の臨床遺伝 HBOCとリンチ症候群. 日産婦誌 2017 ; 69 : 1943-9.
 
23) 大腸癌研究会編. II. リンチ症候群. 遺伝性大腸癌診療ガイドライン 2016年版. 東京 : 金原出版 ; 2016. p.39-81.
 
24) Latham A, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 2019 ; 37 : 286-95.
 
25) Vasen HF, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC) : recommendations by a group of European experts. Gut 2013 ; 62 : 812-23.
PubMed
26) GeneReviews Japan. 疾患別情報 PTEN過誤腫症候群. http://grj.umin.jp/gri/pten.htm
 
27) Pilarski R. Cowden syndrome and the PTEN hamartoma tumor syndrome : systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013 ; 105 : 1607-16.
PubMed
28) http://www.lerner.ccf.org/gmi/ccscore/
 
29) GeneReviews Japan. 疾患別情報 Peutz-Jeghers症候群. http://grj.umin.jp/gri/peuts-jeghers.htm
 
30) Walsh T. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011 ; 108 : 18032-7.
PubMed
31) Tung N. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2015 ; 121 : 25-33.
PubMed
32) Villani A, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome : a prospective observational study. Lancet Oncol 2011 ; 12 : 559-67.
PubMed
33) Espenschied CR. Multigene panel testing provides a new perspective on Lynch syndrome. J Clin Oncol 2017 ; 35 : 2568-75.
PubMed
34) アストラゼネカ/MSD. 乳がん患者へのリムパーザの適応を判定するためのBRCA遺伝学的検査ガイド. 2018. (パンフレット)
 
35) ゲノム医療における情報伝達プロセスに関する提言-がん遺伝子パネル検査と生殖細胞系列全ゲノム/全エクソーム解析について- (初版). 2018. https://www.amed.go.jp/content/000031253.pdf
 
36) Kalia SS, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0) : a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017 ; 19 : 249-55.
 

書評

最近チェックした商品履歴

Loading...